<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intermittent versus daily therapy for treating tuberculosis in children - Bose, A - 2014 | Cochrane Library</title> <meta content="Intermittent versus daily therapy for treating tuberculosis in children - Bose, A - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007953.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intermittent versus daily therapy for treating tuberculosis in children - Bose, A - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007953.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007953.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intermittent versus daily therapy for treating tuberculosis in children" name="citation_title"/> <meta content="Anuradha Bose" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="abose@cmcvellore.ac.in" name="citation_author_email"/> <meta content="Soumik Kalita" name="citation_author"/> <meta content="GlaxoSmithKline Consumer Healthcare" name="citation_author_institution"/> <meta content="Winsley Rose" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Prathap Tharyan" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD007953.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/01/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007953.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007953.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007953.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antitubercular Agents [*therapeutic use]; Drug Administration Schedule; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007953.pub2&amp;doi=10.1002/14651858.CD007953.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="Oy81c7tH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007953\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007953\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007953.pub2",title:"Intermittent versus daily therapy for treating tuberculosis in children",firstPublishedDate:"Jan 28, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007953.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007953.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007953.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007953.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007953.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007953.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007953.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007953.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007953.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007953.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1765 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007953.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-sec-0109"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-sec-0023"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-sec-0024"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-sec-0101"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/appendices#CD007953-sec-0114"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/table_n/CD007953StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/table_n/CD007953StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intermittent versus daily therapy for treating tuberculosis in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information#CD007953-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Anuradha Bose</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information#CD007953-cr-0003">Soumik Kalita</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information#CD007953-cr-0004">Winsley Rose</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information#CD007953-cr-0005">Prathap Tharyan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information/en#CD007953-sec-0128">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 January 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007953.pub2">https://doi.org/10.1002/14651858.CD007953.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007953-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007953-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007953-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007953-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007953-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007953-abs-0001" lang="en"> <section id="CD007953-sec-0001"> <h3 class="title" id="CD007953-sec-0001">Background</h3> <p>Childhood tuberculosis (TB) is a neglected global public health problem. Short treatment courses with rifampicin‐containing anti‐TB drugs given daily for six‐months cure over 90% of infected children, but poor adherence reduces treatment success. Intermittent, short‐course anti‐TB regimens, given two or three times a week under direct observation, are associated with higher adherence in observational studies; but how they compare with daily treatment in relation to cure is unclear. Current international and national recommendations differ on use of intermittent regimens to treat TB in children. </p> </section> <section id="CD007953-sec-0002"> <h3 class="title" id="CD007953-sec-0002">Objectives</h3> <p>To compare the efficacy and safety of intermittent, short‐course anti‐TB regimens (twice‐ or thrice‐weekly) with daily short‐course anti‐TB regimens in treating childhood TB. </p> </section> <section id="CD007953-sec-0003"> <h3 class="title" id="CD007953-sec-0003">Search methods</h3> <p>We searched the Cochrane Infectious Disease Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, clinical trials registries, regional databases, conference proceedings, and references without language restrictions up to 30 May 2013; and contacted experts for relevant published, unpublished, and on‐going trials. </p> </section> <section id="CD007953-sec-0004"> <h3 class="title" id="CD007953-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) and quasi‐RCTs of children aged 15 years or younger, diagnosed with TB (according to the World Health Organization diagnostic categories 1, 2, or 3), who were treated with intermittent twice‐weekly or thrice‐weekly, short‐course anti‐TB regimens compared to daily short‐course anti‐TB treatment regimens. All regimens had to contain rifampicin for at least the first two months. </p> </section> <section id="CD007953-sec-0005"> <h3 class="title" id="CD007953-sec-0005">Data collection and analysis</h3> <p>The review authors independently screened and selected trials, assessed risk of bias, and extracted data. We sought clarifications from trial authors. We pooled relative risks with their 95% confidence intervals and used a random‐effects model where there was significant heterogeneity. We assessed overall evidence‐quality using the GRADE approach. </p> </section> <section id="CD007953-sec-0006"> <h3 class="title" id="CD007953-sec-0006">Main results</h3> <p>We included four trials published between 1996 to 2000 that randomized 563 children (465 evaluable) aged five months to 15 years to intermittent twice‐weekly versus daily anti‐TB treatment. Two trials were from India, one from South Africa, and one from Turkey. All trials used rifampicin and isoniazid, three trials used pyrazinamide, and one trial used streptomycin. The drug combination, and the duration of intermittent and daily treatments differed between trials, and no trials used drug combinations and schedules currently recommended for childhood TB. No trial reported if any child was HIV‐positive. </p> <p>In comparisons of twice‐weekly versus daily anti‐TB treatment regimens, the trials did not detect differences in the number of patients cured, but trials were small, and the comparator regimens were not standard (four trials, 465 children; <i>very low quality evidence</i> ). Trials were underpowered to provide estimates for death (two trials, 213 participants, <i>very low quality evidence</i> ), relapse (one trial, 214 participants,<i>very low quality evidence</i> ), and treatment limiting adverse events (four trials, 441 participants, <i>very low quality evidence)</i> </p> <p>Reported adherence to treatment was similar (87% versus 84%; four trials, 458 children, <i>very low quality evidence</i>) </p> <p>We did not find trials comparing the commonly used thrice‐weekly anti‐TB short‐course regimen with the daily treatment regimen. </p> </section> <section id="CD007953-sec-0007"> <h3 class="title" id="CD007953-sec-0007">Authors' conclusions</h3> <p>Trials conducted to date are insufficient to support or refute the use of intermittent twice‐ or thrice‐weekly, short‐course treatment regimens over daily short‐course treatment in children with TB. Further randomized trials conducted in high TB‐transmission settings will help inform policy and practice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007953-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007953-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007953-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007953-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007953-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007953-abs-0004" lang="en"> <h3>Twice‐ or thrice‐weekly doses versus daily doses of drugs to treat tuberculosis in children </h3> <p>About half a million children are diagnosed with tuberculosis (TB) every year, usually infecting the lungs, but also other organs of the body, and can cause meningitis. Infection in children is relatively common, and so establishing effective drug regimens that are easy to take and monitor is important. </p> <p>TB drug regimens are standardised globally, and include a combination of drugs given daily for six months. More than 95% of children are cured with this treatment. Giving anti‐TB drugs twice‐ or thrice‐weekly is more convenient to supervise than daily treatment but may not be as effective as daily treatment in curing children of TB. The World Health Organization currently recommends only daily treatments, but some national governments recommend twice‐ or thrice‐weekly doses for children with TB. </p> <p>In this Cochrane review, the review authors compared children given intermittent anti‐TB treatment to those given daily treatment. They examined the evidence up to 30 May 2013 and included four randomized trials that compared twice‐weekly treatment with daily doses of anti‐TB drugs, but none evaluated thrice‐weekly dosing. The four trials included 563 children aged five months to 15 years, not known to be resistant to TB drugs. The trials were published over 12 years ago and the regimens used are not those currently recommended. </p> <p>The trials were small, and did not detect a difference between twice‐weekly or daily treatment in the number of children who were cured, died, relapsed, reported taking most or all of the drugs, or had adverse effects. Whether regimens of drugs two or three times a week are as good as regimens with daily doses remains unclear, as the evidence base to date is small, and the regimens tested are not the same as currently currently recommended drug combinations. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007953-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007953-sec-0109"></div> <h3 class="title" id="CD007953-sec-0110">Implications for practice</h3> <section id="CD007953-sec-0110"> <p>There is insufficient evidence to support or refute the use of intermittent (twice‐weekly or thrice‐weekly) short‐course treatment regimens over daily short‐course treatment in children with TB. Intermittent and daily regimens may have similar effects in children with TB, but further research is required to confirm the observations in this review. However, the <a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a> strongly recommends against the use of intermittent anti‐TB treatment regimens in HIV‐positive children. </p> </section> <h3 class="title" id="CD007953-sec-0111">Implications for research</h3> <section id="CD007953-sec-0111"> <p>Evidence from randomized controlled trials on these regimens is limited, and trials could help inform national and international public health policies for regimens in treating paediatric TB. </p> <p>We propose that adequately powered, multicentre, multi‐country, randomized, non‐inferiority, pragmatic trials conducted in high TB‐transmission settings, in low and middle‐income countries that compare thrice‐weekly, and daily short‐course (six months) dosing, and use the currently recommended four drugs, in HIV‐negative children would help inform policy. Twice‐weekly regimens are not as commonly used as thrice‐weekly regimens and it would be important to establish the equivalence of thrice weekly regimens before considering trials of twice‐weekly anti‐TB regimens. Some national TB control programmes, such the one in India (<a href="./references#CD007953-bbs2-0097" title="Revised National Tuberculosis Control Programme. National guidelines on diagnosis and treatment of pediatric tuberculosis. http://tbcindia.nic.in/documents.html. Directorate General of Health Services. Ministry of Health and Family Welfare, (accessed 1 November 2012). ">RNTCP 2012</a>), recommend only fully‐intermittent thrice‐weekly treatment under DOT, and thrice weekly fully intermittent treatment versus partially‐intermittent treatment (with initial daily dosing for the first two months) should also be evaluated in similar separate trials. Suggested design, conduct and reporting considerations for such trials are provided in <a href="./appendices#CD007953-sec-0119">Appendix 4</a>. </p> <p>In addition, national TB control programmes that treat children with TB routinely with intermittent regimens, should regularly report treatment success rates along with the criteria used to evaluate treatment success. They should also report adherence rates, relapse rates, and rates of adverse events, in order to build the evidence‐base for programmatic success with intermittent regimens. This is important since the WHO rapid evidence guidance based the recommendations for the continued use of thrice‐weekly, intermittent treatments in HIV‐negative children in the continuation phase of therapy, in spite of low quality evidence, on the consideration that children living in countries where intermittent treatment is given as part of national TB control programmes should not be excluded from the benefits of treatment (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>). Such reports will then provide valuable updates of the benefits of intermittent treatment from programmatic evaluations to supplement data from future RCTs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007953-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007953-sec-0023"></div> <div class="table" id="CD007953-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intermittent short‐course anti‐TB regimens compared to daily anti‐TB regimens for treating TB in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intermittent short‐course anti‐TB regimens compared to daily anti‐TB regimens for treating TB in children with TB</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Children with TB<sup>1</sup> <br/> <b>Intervention:</b> Intermittent short‐course twice‐weekly anti‐TB regimens (six to nine months)<br/> <b>Comparison:</b> Daily anti‐TB regimens (six to 12 months) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Daily anti‐TB regimens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intermittent short‐course anti‐TB regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cure</b> </p> <p>Follow‐up: 12 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>836 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>844 per 1000</b> <br/> (786 to 920) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/> (0.94 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death from any cause</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (2 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.52</b> <br/> (0.26 to 8.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213<br/> (2 trials)<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>,3,7,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> </p> <p>Follow‐up: 12 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.68</b> <br/> (0.15 to 89.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214<br/> (1 trial)<sup>10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>11,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence to treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>840 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>874 per 1000</b> <br/> (815 to 932) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> (0.97, 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>3,4,14,15</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐limiting adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (1 to 39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.4</b> <br/> (0.06 to 2.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,16</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies for pooled data and the control group risk for data from single studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The data in this table are from <a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a>; <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a>; <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a>; and <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>.<br/> <sup>2</sup> Downgraded by 1 for serious risk of bias: None of the trials were free of risk of bias. The trial that contributed the most weight (43%) to the pooled effect estimates (<a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>) was at high risk of selection bias.<br/> <sup>3</sup> No serious inconsistency<i>:</i> Statistical heterogeneity was low.<br/> <sup>4</sup> Downgraded by 1 for serious indirectness: Two of the trials (<a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a>; <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a>) used a longer duration of treatment in the daily treatment arms than in the intermittent arms, and the intermittent arms in <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> and <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> used non‐standard regimens. None used drug combinations and schedules currently recommended for childhood TB.<br/> <sup>5</sup> Downgraded by 1 for serious imprecision: The 95% CI of the effect estimate indicated only non‐appreciable benefit with both interventions, but the sample size was smaller than the optimal information size for equivalence.<br/> <sup>6</sup> Data for deaths are from only two of the four trials as no deaths were reported in <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> and <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>.<br/> <sup>7</sup> Downgraded by 1 for serious risk of bias: The trials were either unclear or at high risk of selection bias.<br/> <sup>8</sup> Downgraded by 1 for serious indirectness: Neither control group used drug combinations and schedules currently recommended for childhood TB.<br/> <sup>9</sup> Downgraded by 1 for serious imprecision: The number of deaths was very few, and the 95% CI for the risk difference are wide. </p> <p><sup>10</sup> Data for relapse are from only one trial (<a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>) as no participant was reported to have had a confirmed relapse in <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a>; <a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a>; and <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> over one to five years of follow‐up.<br/> <sup>11</sup> No serious study limitations: Only one relapse was reported with intermittent treatment in <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>. This trial was at high risk of selection bias, but this is unlikely to have introduced bias in relapse estimates.<br/> <sup>12</sup> Downgraded by 1 for serious indirectness: The data for relapse comes from only one trial conducted in South Africa nearly 20 years ago and may not generalize to other settings today. </p> <p><sup>13</sup>Downgraded by 2 for serious imprecision: Only one child relapsed and the upper and lower limits of the 95% CI indicate appreciable benefits for both interventions with so significant differences.<br/> <sup>14</sup> Downgraded by 1 for serious risk of bias<i>:</i> The trials were open label in design and assessments of adherence were not done blind to treatment allocation The four trials used different methods to assess adherence and different definitions to define those adherent.<br/> <sup>15</sup> Downgraded by 1 for serious imprecision: The 95% CI of the pooled effect estimates indicated that the interventions did not appreciably increase adherence.<br/> <sup>16</sup> Downgraded by 1 for serious imprecision<i>:</i> Adverse events were infrequent and the 95% CI of the absolute risk difference indicated a non‐appreciable difference in the risk of adverse events requiring treatment interruptions with intermittent and with daily treatments. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007953-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007953-sec-0024"></div> <section id="CD007953-sec-0025"> <h3 class="title" id="CD007953-sec-0025">Description of the condition</h3> <p>Childhood tuberculosis (TB) is a major public health problem that was not considered a priority, (in public health, as authors we think the statement is clear as it is) due to difficulties in accurate diagnosis and a lack of reliable data on its prevalence (<a href="./references#CD007953-bbs2-0113" title="WallsT , ShingadiaD . Global epidemiology of paediatric tuberculosis. Journal of Infection2004;48(1):13‐22. ">Walls 2004</a>; <a href="./references#CD007953-bbs2-0054" title="BrentAJ , AndersonST , KampmannB . Childhood tuberculosis: out of sight, out of mind?. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(3):217‐8. ">Brent 2008</a>). The World Health Organization (WHO) estimates that there were between 470,000 to 510,000 new cases of childhood TB worldwide in 2011, equivalent to approximately 6% of the global 8.3 to nine million new adult TB cases (<a href="./references#CD007953-bbs2-0118" title="World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization, 2012. ">WHO 2012</a>). Also, there were 64,000 deaths among HIV‐negative children less than 15 years old (<a href="./references#CD007953-bbs2-0118" title="World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization, 2012. ">WHO 2012</a>). Around 75% of the global incidence of childhood TB occurs in 22 high‐burden countries (<a href="./references#CD007953-bbs2-0058" title="CorbettEL , WattCJ , WalkerN , MaherD , WilliamsBG , RaviglioneMC , et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine2003;163(9):1009‐21. ">Corbett 2003</a>). India and China are the countries with the highest TB burden and together contribute nearly 40% of the global incidence of TB annually (<a href="./references#CD007953-bbs2-0118" title="World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization, 2012. ">WHO 2012</a>). </p> <p>Prevalence of childhood TB varies between countries. In industrialized countries it comprises a mere 5% of the total TB burden; in low‐income countries this proportion is as high as 40%; and in some of these countries childhood TB incidence is 50% of the adult TB incidence (<a href="./references#CD007953-bbs2-0051" title="BeyersN , GieRP , ZietsmanHL , KunnekeM , HaumanJ , TatleyM , et al. The use of a geographical information system (GIS) to evaluate the distribution of tuberculosis in a high‐incidence community. South African Medical Journal1996;86(1):40‐4. ">Beyers 1996</a>; <a href="./references#CD007953-bbs2-0093" title="NelsonLJ , WellsCD . Global epidemiology of childhood tuberculosis. International Journal of Tuberculosis and Lung Disease2004;8(5):636‐47. ">Nelson 2004</a>; <a href="./references#CD007953-bbs2-0076" title="International Institute for Population Sciences (IIPS) and Macro International. National Family Health Survey (NFHS‐3), 2005‐06: India. National Family Health Survey‐32007; Vol. 1:411. ">IIPS 2007</a>; <a href="./references#CD007953-bbs2-0088" title="MaraisBJ , SchaafHS . Childhood tuberculosis: An emerging and previously neglected problem. Infectious Diseases Clinics of North America2010;24(3):729‐49. ">Marais 2010</a>). Even high‐income countries have been unable to match the decline in childhood TB incidence to that achieved in adult TB (<a href="./references#CD007953-bbs2-0055" title="Centers for Disease Control and Prevention. Tuberculosis morbidity ‐ United States, 1994. MMWR. Morbidity and mortality weekly report1995;44(20):387‐9, 395. ">CDC 1995</a>). In fact, the incidence of childhood TB in both Europe and North America has recently increased, largely due to immigration from endemic areas (<a href="./references#CD007953-bbs2-0084" title="MagdorfK , DetjenAK . Proposed management of childhood tuberculosis in low‐incidence countries. European Journal of Pediatrics2008;167(8):927‐38. ">Magdorf 2008</a>; <a href="./references#CD007953-bbs2-0094" title="NewtonSM , BrentAJ , AndersonS , WhittakerE , KampmannB . Paediatric tuberculosis. Lancet Infectious Diseases2008;8(8):498‐510. ">Newton 2008</a>). </p> <p>Reports on the burden of TB generated by different countries rely on diagnosis by expectorated sputum stains that are positive for acid fast <i>Mycobacterium tuberculosis</i> bacilli (using special stains). However, smears are not routinely done in children in many countries with a high burden of TB; younger children rarely produce sputum, and childhood TB is largely sputum smear‐negative, resulting in an under‐estimation of prevalence (<a href="./references#CD007953-bbs2-0102" title="ShingadiaD , NovelliV . Diagnosis and treatment of tuberculosis in children. Lancet Infectious Diseases2003;3(10):624‐32. ">Shingadia 2003</a>; <a href="./references#CD007953-bbs2-0094" title="NewtonSM , BrentAJ , AndersonS , WhittakerE , KampmannB . Paediatric tuberculosis. Lancet Infectious Diseases2008;8(8):498‐510. ">Newton 2008</a>; <a href="./references#CD007953-bbs2-0118" title="World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization, 2012. ">WHO 2012</a>). </p> <section id="CD007953-sec-0026"> <h4 class="title">Diagnosis of childhood TB</h4> <p>Diagnosis of childhood TB is difficult because of the lack of specificity of diagnostic criteria. Unlike adult TB, where sputum‐positivity confirms the diagnosis, it is difficult to obtain sputum from children and many centres do not have facilities for bacterial culture after gastric aspiration (gastric lavage). Sputum microscopy is positive in under 10% to 15% of children with probable TB and under 30% to 40% of sputum cultures are positive (<a href="./references#CD007953-bbs2-0087" title="MaraisBJ , PaiM . Recent advances in the diagnosis of childhood tuberculosis. Archives of Disease in Childhood2007;92(5):446‐52. ">Marais 2007</a>). While this could contribute to underestimation of childhood TB prevalence, the non‐specific nature of clinical diagnostic criteria might also result in an over‐diagnosis of TB, with the possibility that around 15% to 20% of the children diagnosed in high‐incidence communities may not have TB (<a href="./references#CD007953-bbs2-0093" title="NelsonLJ , WellsCD . Global epidemiology of childhood tuberculosis. International Journal of Tuberculosis and Lung Disease2004;8(5):636‐47. ">Nelson 2004</a>). </p> <p>The WHO recommends that TB diagnosis is based on careful history, clinical examination, tuberculin skin testing, and, wherever possible, bacterial confirmation (<a href="./references#CD007953-bbs2-0107" title="Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 1: Introduction and diagnosis of tuberculosis in children. International Journal of Tuberculosis and Lung Disease2006;10(10):1091‐7. ">Stop TB Partnership 2006a</a>; <a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>). The symptoms indicative of childhood TB are chronic cough for over 21 days, fever for more than 14 days (after excluding malaria or other causes of pneumonia), loss of weight, and failure to gain weight (<a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>). </p> </section> </section> <section id="CD007953-sec-0027"> <h3 class="title" id="CD007953-sec-0027">Description of the intervention</h3> <p>The recommended treatment for childhood TB is divided into two phases: an intensive phase and a continuation phase (<a href="./appendices#CD007953-sec-0115">Appendix 1</a>). The intensive phase aims to help eliminate the majority of <i>M. tuberculosis</i> bacteria and prevent any emerging drug resistance; in the continuation phase the aim is to eradicate the dormant bacteria (<a href="./references#CD007953-bbs2-0108" title="Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 2: Anti‐tuberculosis treatment in children. International Journal of Tuberculosis and Lung Disease2006;10(11):1205‐11. ">Stop TB Partnership 2006b</a>; <a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>). </p> <p>Short‐course treatments given daily or intermittently (twice‐ or thrice‐weekly) over six months to one year are commonly used in national TB control programs, and are based on treatment regimens in adults due to convenience in implementation (<a href="./references#CD007953-bbs2-0068" title="GrahamSM , GieRM , SchaafHS , CoulterJB , EspinalMA , BeyersN . Childhood tuberculosis: clinical research needs. International Journal of Tuberculosis and Lung Disease2004;85(5):648‐57. ">Graham 2004</a>). Over 95% of childhood TB cases can be successfully treated with short‐course treatments, but rates of successful treatment are often much lower in low‐income countries, due to poorer compliance and treatment completion rates, delayed diagnosis, wrong diagnoses, co‐infection with HIV, poor absorption of anti‐TB drugs in malnourished or HIV‐infected children, and also due to drug resistance (<a href="./references#CD007953-bbs2-0068" title="GrahamSM , GieRM , SchaafHS , CoulterJB , EspinalMA , BeyersN . Childhood tuberculosis: clinical research needs. International Journal of Tuberculosis and Lung Disease2004;85(5):648‐57. ">Graham 2004</a>). The potential for drug resistance with intermittent regimens is also a matter of concern in studies in adults. There is a lower risk of children with TB developing drug resistance as childhood TB is mostly paucibacillary (involves few bacilli) (<a href="./references#CD007953-bbs2-0062" title="DonaldPR , SchaafHS . Old and new drugs for the treatment of tuberculosis in children. Paediatric Respiratory Reviews2007;8(2):134–41. ">Donald 2007a</a>), and it is thought that children do not contribute to the transmission of drug‐resistant TB (<a href="./references#CD007953-bbs2-0088" title="MaraisBJ , SchaafHS . Childhood tuberculosis: An emerging and previously neglected problem. Infectious Diseases Clinics of North America2010;24(3):729‐49. ">Marais 2010</a>). However, drug resistance in adult populations in some parts of the world is rising, and drug resistance in children reflects the community transmission of drug‐resistant strains from adults (<a href="./references#CD007953-bbs2-0094" title="NewtonSM , BrentAJ , AndersonS , WhittakerE , KampmannB . Paediatric tuberculosis. Lancet Infectious Diseases2008;8(8):498‐510. ">Newton 2008</a>; <a href="./references#CD007953-bbs2-0099" title="SchaafHS , MaraisBJ , HesselingAC , BrittleW , DonaldPR . Surveillance of antituberculosis drug resistance from the Western Cape province of South Africa‐ an upward trend. American Journal of Public Health2009;99(8):1486‐90. ">Schaaf 2009</a>). Recent studies have demonstrated the potential for drug‐resistant TB to be transmitted within families by infected children (<a href="./references#CD007953-bbs2-0101" title="SeddonJA ,  WarrenRM ,  EnarsonDA ,  BeyersN ,  SchaafHS . Drug‐resistant tuberculosis transmission and resistance amplification within families. Emerging Infectious Diseases2012;18(8):1342‐5. ">Seddon 2012</a>). </p> <section id="CD007953-sec-0028"> <h4 class="title">Drugs used for childhood TB</h4> <p>Drugs used to treat children with TB are isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin. Corticosteroids (prednisolone) are recommended for all children with TB meningitis. The WHO recommends that TB in children infected with HIV should be treated as in those without HIV infection: with a six‐month regimen (<a href="./references#CD007953-bbs2-0108" title="Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 2: Anti‐tuberculosis treatment in children. International Journal of Tuberculosis and Lung Disease2006;10(11):1205‐11. ">Stop TB Partnership 2006b</a>; <a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>). Rifampicin and isoniazid are bactericidal drugs, with isoniazid being the most potent drug, killing around 90% of the bacteria within 48 hours; rifampicin is half as potent as isoniazid (<a href="./references#CD007953-bbs2-0064" title="DonaldPR , DiaconAH . The early bactericidal activity of anti‐tuberculosis drugs: a literature review. Tuberculosis2008;88(Suppl 1):S75‐83. ">Donald 2008</a>). Rifampicin and pyrazinamide are sterilizing agents that eliminate persisting, intermittently active or dormant bacilli, and without which any short‐course treatment should ideally not be given (<a href="./references#CD007953-bbs2-0063" title="DonaldPR . The treatment of tuberculosis in childhood. South African Medical Journal2007;97(10 Pt 2):992‐4. ">Donald 2007b</a>). </p> </section> <section id="CD007953-sec-0029"> <h4 class="title">Diagnostic categories and treatment regimens</h4> <p>TB treatment regimens differ according to the diagnostic categories (see <a href="./appendices#CD007953-sec-0115">Appendix 1</a>): Category 1 comprises new cases (new smear‐positive pulmonary TB; new smear‐negative pulmonary TB with extensive parenchymal lesions; severe forms of extrapulmonary TB; severe concomitant HIV disease). Category 2 comprises previously treated smear‐positive pulmonary TB cases. Category 3 is made up of new smear‐negative pulmonary TB cases other than those in category 1. Category 4 comprises chronic and multiple‐drug resistant TB (<a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>; <a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>). </p> </section> <section id="CD007953-sec-0030"> <h4 class="title">Drug doses</h4> <p>Most TB drug regimens worldwide have been based on studies in adults and therefore for children the same mg/kg/bodyweight doses were given as in adults. However, this practice has been challenged (<a href="./references#CD007953-bbs2-0098" title="SchaafHS , ParkinDP , SeifartHI , WerelyCJ , HesselingPB , vanHeldenPD , et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Archives of Disease in Childhood2005;90(6):614‐8. ">Schaaf 2005</a>). Several studies have attempted to determine the effective doses of anti‐TB drugs in children, but the recommendations in many are discordant (<a href="./references#CD007953-bbs2-0047" title="AbernathyRS , DuttAK , SteadWW , MoersDJ . Short‐course chemotherapy for tuberculosis in children. Pediatrics1983;72(6):801‐6. ">Abernathy 1983</a>; <a href="./references#CD007953-bbs2-0112" title="VarudkarBL . Short‐course chemotherapy for tuberculosis in children. Indian Clinical Journal of Pediatrics1985;52(419):593‐7. ">Varudkar 1985</a>; <a href="./references#CD007953-bbs2-0052" title="BiddulphJ , KokohaV , SharmaSS . Short course chemotherapy in childhood tuberculosis. Journal of Tropical Pediatrics1988;34(1):20‐3. ">Biddulph 1988</a>; <a href="./references#CD007953-bbs2-0103" title="SniderDE , RiederHL , CombsD , BlochAB , HaydenCH , SmithMH . Tuberculosis in children. Pediatric Infectious Disease Journal1988;7(4):271‐8. ">Snider 1988</a>; <a href="./references#CD007953-bbs2-0104" title="StarkeJR , Taylor‐WattsKT . Tuberculosis in the pediatric population of Houston, Texas. Pediatrics1989;84(1):28‐35. ">Starke 1989a</a>; <a href="./references#CD007953-bbs2-0105" title="StarkeJR , Taylor‐WattsKT . Six month chemotherapy of intrathoracic tuberculosis in children. American Reviews of Respiratory Diseases1989;139(suppl):A314. ">Starke 1989b</a>; <a href="./references#CD007953-bbs2-0048" title="AcocellaG . The use of fixed dose combinations in antituberculous chemotherapy. Rationale for their application in daily, intermittent and pediatric regimens. Bulletin of the International Union against Tuberculosis and Lung Disease1990;65(2‐3):77‐83. ">Acocella 1990</a>; <a href="./references#CD007953-bbs2-0053" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a>; <a href="./references#CD007953-bbs2-0095" title="ReisFJ , BedranMB , MouraJA , AssisI , RodriguesME . Six‐month isoniazid‐rifampin treatment for pulmonary tuberculosis in children. American Review of Respiratory Disease1990;142(5):996‐9. ">Reis 1990</a>; <a href="./references#CD007953-bbs2-0106" title="StarkeJR . Multidrug therapy for tuberculosis in children. Pediatric Infectious Disease Journal1990;9(11):785‐93. ">Starke 1990</a>; <a href="./references#CD007953-bbs2-0059" title="CroftonJ , HorneN , MillerF . Clinical tuberculosis. 2nd Edition. London: Macmillan Education, 1999. ">Crofton 1992</a>; <a href="./references#CD007953-bbs2-0005" title="Al‐DossaryFS , OngLT , CorreaAG , StarkeJR . Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy. Pediatric Infectious Disease Journal2002;21(2):91‐7. ">Al‐Dossary 2002</a>; <a href="./references#CD007953-bbs2-0040" title="SwaminathanS , RaghavanA , DuraipandianM , KripasankarAS , RamachandranP . Short‐course chemotherapy for paediatric respiratory tuberculosis: 5‐year report. International Journal of Tuberculosis and Lung Disease2005;9(6):693‐6. ">Swaminathan 2005</a>; <a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>). Experts commissioned by the WHO conducted pharmacokinetic studies to determine the optimum doses of first line drugs used to treat childhood TB (rifampicin, isoniazid, and pyrazinamide); and the safety of these recommended doses of these drugs needs to be clarified in trials in children, especially those under 12 years of age (<a href="./references#CD007953-bbs2-0073" title="HillS , RegondiL , GrzemskaM , MatiruaR . Children and tuberculosis medicines: bridging the research gap. Bulletin of the World Health Organization2008;86(9):658. ">Hill 2008</a>). Current recommended doses for TB treatment in children for the initial two months and the four months of continuation treatment (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>) are higher than those used previously: isoniazid 10 mg/kg (range 10 to 15 mg/kg), maximum dose 300 mg/day; rifampicin 15 mg/kg (range 10 to 20 mg/kg), maximum dose 600 mg/day; pyrazinamide 35 mg/kg (30 to 40 mg/kg; maximum dose per day is 2000 mg; and ethambutol 20 mg/kg (15 to 25 mg/kg) dose dependant pharmacokinetic evidence and observational studies support the revised WHO recommendations (<a href="./references#CD007953-bbs2-0065" title="DonaldPR . Antituberculosis drug‐induced hepatotoxicity in children. Pediatric Reports2011;3(2):e16. ">Donald 2011</a>; <a href="./references#CD007953-bbs2-0111" title="TheeS , SeddonJA , DonaldPR , SeifartHI , WerelyCJ , HesselingAC , et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrobrobial Agents and Chemotherapy2011;55(12):5560‐7. ">Thee 2011</a>; <a href="./references#CD007953-bbs2-0081" title="KiserJJ , ZhuR , D'ArgenioDZ , CottonMF , BobatR , McSherryGD , et al. Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. Therapeutic Drug Monitoring2012;34(4):446‐51. ">Kiser 2012</a>). </p> </section> <section id="CD007953-sec-0031"> <h4 class="title">Treatment adherence, cure, and relapse</h4> <p>One of the most important challenges for any anti‐TB programme is reducing the number of people who default, or discontinue treatment. The WHO defines a defaulter as a patient whose treatment was interrupted for two or more consecutive months (<a href="./references#CD007953-bbs2-0114" title="World Health Organization. Communicable diseases: tuberculosis, fact sheets on TB, TB and children. http://www.searo.who.int/EN/Section10/Section2097/Section2106_10681.htm (accessed 27 April 2009). ">WHO 2006a</a>; <a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>). When a child is sputum‐negative in the last month of treatment for TB, and also on at least one previous occasion, he or she can be deemed cured (<a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>), though this applies only to sputum‐positive pulmonary TB. In practice, resolution of clinical symptoms with significant weight gain, complete or partial resolution of radiological findings without the emergence of new radiological lesions, disappearance of lymph nodes in TB lymphadenitis, and regression in the size of any enlarged organs for disseminated TB are taken as equivalent to treatment response or cure. Some national guidelines for paediatric TB do not put a time limit after completion of treatment and the re‐appearance of disease (<a href="./references#CD007953-bbs2-0075" title="Indian Academy of Pediatric(IAP) , Working group on tuberculosis. Consensus statement on childhood tuberculosis. Indian Pediatrics2010;47(1):41‐55. ">IAP 2010</a>; <a href="./references#CD007953-bbs2-0097" title="Revised National Tuberculosis Control Programme. National guidelines on diagnosis and treatment of pediatric tuberculosis. http://tbcindia.nic.in/documents.html. Directorate General of Health Services. Ministry of Health and Family Welfare, (accessed 1 November 2012). ">RNTCP 2012</a>). However re‐emergence of signs and symptoms of TB within 12 months after stopping treatment would appear to be a more appropriate cut‐off as re‐emergence of symptoms beyond this time would more likely be due to re‐infection in countries with a high‐TB burden, and not a relapse due to treatment failure (<a href="./references#CD007953-bbs2-0092" title="MwandumbaHC , SquireSB . Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD000970] ">Mwandumba 2001</a>). </p> </section> </section> <section id="CD007953-sec-0032"> <h3 class="title" id="CD007953-sec-0032">How the intervention might work</h3> <p>Fully‐intermittent drug regimens for childhood TB require the child to take drugs just two or three times a week, preferably under direct observation and often preceded by daily treatment in the intensive phase (partially‐intermittent treatment). The rationale for intermittent dosing was the observation <i>in vitro</i> that following interruption of treatment with anti‐TB drugs, growth of <i>M. tuberculosis</i> takes some days to resume, thereby suggesting that short interruptions would be possible before resuming treatment; this interval is decided by the shortest time taken for resumption of bacterial activity after drug cessation that varies with anti‐TB drugs, and is shortest for rifampicin at two to three days (<a href="./references#CD007953-bbs2-0061" title="DickinsonJM , MitchisonDA . In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle1966;47(4):370‐80. ">Dickinson 1966</a>). In observational studies, this not only reduced the need for hospitalization for drug delivery but also increased compliance amongst children on anti‐TB drugs (<a href="./references#CD007953-bbs2-0047" title="AbernathyRS , DuttAK , SteadWW , MoersDJ . Short‐course chemotherapy for tuberculosis in children. Pediatrics1983;72(6):801‐6. ">Abernathy 1983</a>; <a href="./references#CD007953-bbs2-0052" title="BiddulphJ , KokohaV , SharmaSS . Short course chemotherapy in childhood tuberculosis. Journal of Tropical Pediatrics1988;34(1):20‐3. ">Biddulph 1988</a>; <a href="./references#CD007953-bbs2-0080" title="KiperN , GöçmenA , DilberE , OzçelikU . Effectiveness of short‐course, intermittent chemotherapy for tuberculosis in children. Clinical Pediatrics1998;37(7):433‐6. ">Kiper 1998</a>; <a href="./references#CD007953-bbs2-0005" title="Al‐DossaryFS , OngLT , CorreaAG , StarkeJR . Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy. Pediatric Infectious Disease Journal2002;21(2):91‐7. ">Al‐Dossary 2002</a>; <a href="./references#CD007953-bbs2-0040" title="SwaminathanS , RaghavanA , DuraipandianM , KripasankarAS , RamachandranP . Short‐course chemotherapy for paediatric respiratory tuberculosis: 5‐year report. International Journal of Tuberculosis and Lung Disease2005;9(6):693‐6. ">Swaminathan 2005</a>). </p> <p>While treatment regimens for active TB that are intermittent, or use rifampin as part of combination treatment only during the initial phase, may offer practical advantages, their efficacy has often been in doubt. In a systematic review and meta‐analysis of studies in adults, TB treatment outcomes were significantly worse with shorter duration of rifampicin, or with initial drug resistance to isoniazid, or streptomycin, or both (<a href="./references#CD007953-bbs2-0091" title="MenziesD , BenedettiA , PaydarA , MartinI , RoyceS , PaiM , et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes:A systematic review and meta‐analysis. PLoS Medicine2009;6(9):e1000146. ">Menzies 2009</a>). Treatment outcomes were similar with all intermittent schedules evaluated, but there was insufficient evidence to support administration of treatment twice‐weekly throughout therapy (<a href="./references#CD007953-bbs2-0091" title="MenziesD , BenedettiA , PaydarA , MartinI , RoyceS , PaiM , et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes:A systematic review and meta‐analysis. PLoS Medicine2009;6(9):e1000146. ">Menzies 2009</a>). </p> </section> <section id="CD007953-sec-0033"> <h3 class="title" id="CD007953-sec-0033">Why it is important to do this review</h3> <section id="CD007953-sec-0034"> <h4 class="title">The importance of treating childhood TB for global TB control</h4> <p>Most treatment strategies for childhood TB are based on the management of TB in adults (<a href="./references#CD007953-bbs2-0085" title="MandalakasAM , StarkeJR . Current concepts of childhood tuberculosis. Seminars in Pediatric Infectious Diseases2005;16(2):93‐104. ">Mandalakas 2005</a>), the rationale being that targeting adults with TB will automatically help reduce the incidence and prevalence of TB in children (<a href="./references#CD007953-bbs2-0069" title="HeymannSJ , BrewerTF , WilsonME , ColditzGA , FinebergHV . Pediatric tuberculosis: what needs to be done to decrease morbidity and mortality. Pediatrics2000;106(1):e1. ">Heymann 2000</a>). Estimates from modelling studies suggest that even small increases in case detection and treatment of childhood TB would save millions more children's lives compared to the effect that treating increasing number of adults with TB would have on TB in children (<a href="./references#CD007953-bbs2-0069" title="HeymannSJ , BrewerTF , WilsonME , ColditzGA , FinebergHV . Pediatric tuberculosis: what needs to be done to decrease morbidity and mortality. Pediatrics2000;106(1):e1. ">Heymann 2000</a>). Thus, a 5% increase in the number of children on anti‐TB treatment is estimated to lead to a 25% decline in the prevalence of childhood TB and also a 16% decline in mortality due to TB after 10 years, compared to no intervention (<a href="./references#CD007953-bbs2-0055" title="Centers for Disease Control and Prevention. Tuberculosis morbidity ‐ United States, 1994. MMWR. Morbidity and mortality weekly report1995;44(20):387‐9, 395. ">CDC 1995</a>). </p> <p>Untreated latent TB infection in children acts as a reservoir for future disease but since most active disease in children occurs in the first year after infection, the presence of childhood TB in a community is an indication of the ongoing disease transmission, including drug‐resistant strains, within it (<a href="./references#CD007953-bbs2-0079" title="KantL . Childhood tuberculosis: increasing but neglected. Indian Journal of Tuberculosis2001;48(1):1‐2. ">Kant 2001</a>; <a href="./references#CD007953-bbs2-0086" title="MaraisBJ , GieRP , SchaafHS , HesselingAC , ObiharaCC , StarkeJJ , et al. The natural history of childhood intra‐thoracic tuberculosis: a critical review of literature from the pre‐chemotherapy era. International Journal of Tuberculosis and Lung Disease2004;8(4):392‐402. ">Marais 2004</a>; <a href="./references#CD007953-bbs2-0094" title="NewtonSM , BrentAJ , AndersonS , WhittakerE , KampmannB . Paediatric tuberculosis. Lancet Infectious Diseases2008;8(8):498‐510. ">Newton 2008</a>). </p> <p>The control of childhood TB now forms part of the 'Stop TB' strategy (<a href="./references#CD007953-bbs2-0107" title="Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 1: Introduction and diagnosis of tuberculosis in children. International Journal of Tuberculosis and Lung Disease2006;10(10):1091‐7. ">Stop TB Partnership 2006a</a>; <a href="./references#CD007953-bbs2-0108" title="Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 2: Anti‐tuberculosis treatment in children. International Journal of Tuberculosis and Lung Disease2006;10(11):1205‐11. ">Stop TB Partnership 2006b</a>; <a href="./references#CD007953-bbs2-0109" title="Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 3: Management of TB in the HIV‐infected child. International Journal of Tuberculosis and Lung Disease2006;10(12):1331‐6. ">Stop TB Partnership 2006c</a>; <a href="./references#CD007953-bbs2-0110" title="Stop TB Partnership Childhood TB Subgroup: World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 4: Childhood contact screening and management. International Journal of Tuberculosis and Lung Diseases2007;11(1):12‐5. ">Stop TB Partnership 2007</a>) that builds on the WHO's DOTS (Directly Observed Treatment, Short‐course) programme (<a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>), co‐developed by the International Union Against Tuberculosis and Lung Disease (IUTLD); and that aims to contribute to achieving goals four and six (to reduce child mortality and to improve maternal health) of the United Nations' Millennium Development Goals (<a href="http://www.undp.org/mdg/" target="_blank">http://www.undp.org/mdg/</a>). </p> </section> <section id="CD007953-sec-0035"> <h4 class="title">Differences in international and national recommendations</h4> <p>Inappropriate prescription of anti‐TB drugs for adults and children is common (<a href="./references#CD007953-bbs2-0082" title="LangendamMW , van derWerfMJ , HuitricE , ManisseroD . Prevalence of inappropriate tuberculosis treatment regimens: a systematic review. European Respiratory Journal2012;39(4):1012‐20. ">Langendam 2012</a>). There are also discrepancies in national and international recommendations for treatment schedules in high‐, low‐, and middle‐income countries and sometimes even within the same country. The WHO and the British Thoracic Society recommend either the daily or thrice‐weekly intermittent regimens, whereas the American Thoracic Society, along with the Centers for Disease Control and Prevention (CDC), recommend a daily or twice‐weekly regimen (<a href="./references#CD007953-bbs2-0102" title="ShingadiaD , NovelliV . Diagnosis and treatment of tuberculosis in children. Lancet Infectious Diseases2003;3(10):624‐32. ">Shingadia 2003</a>). Current Indian guidelines recommend thrice‐weekly intermittent therapy given by DOTS in both the intensive phase and the continuation phase (<a href="./references#CD007953-bbs2-0075" title="Indian Academy of Pediatric(IAP) , Working group on tuberculosis. Consensus statement on childhood tuberculosis. Indian Pediatrics2010;47(1):41‐55. ">IAP 2010</a>; <a href="./references#CD007953-bbs2-0097" title="Revised National Tuberculosis Control Programme. National guidelines on diagnosis and treatment of pediatric tuberculosis. http://tbcindia.nic.in/documents.html. Directorate General of Health Services. Ministry of Health and Family Welfare, (accessed 1 November 2012). ">RNTCP 2012</a>). All TB cases are to be reported to the Revised National Tuberculosis Control Programme (RNTCP), which supplies free drugs for treatment under the DOTS programme (<a href="./references#CD007953-bbs2-0057" title="ChauhanLS , AroraVK . Formulation of guidelines for diagnosis and treatment of paediatric TB cases under RNTCP. Indian Journal of Tuberculosis2004;51(1):102‐5. ">Chauhan 2004</a>). </p> <p>Differences in recommendations have resulted in clinicians using a myriad of regimens. In India, the earlier Indian Academy of Paediatrics (IAP) recommendation of the daily regimen (<a href="./references#CD007953-bbs2-0074" title="Indian Academy of Pediatrics (IAP) Working Group. Treatment of childhood tuberculosis: consensus statement of IAP Working Group. Indian Pediatrics1997;34(12):1093‐6. ">IAP 1997</a>) aimed primarily at paediatricians in the private sector (<a href="./references#CD007953-bbs2-0049" title="AmdekarY . Changes in the management of tuberculosis. Indian Journal of Pediatrics2009;76(7):739‐42. ">Amdekar 2009</a>), led to the preferential use of daily dosing for their patients. The national programme, on the other hand, provides only intermittent therapy. Such a dichotomy resulted in a substantial proportion of patients not being registered in the National TB Control Programme statistics, since they did not access the drugs given under this programme. The more recent consensus statement (<a href="./references#CD007953-bbs2-0075" title="Indian Academy of Pediatric(IAP) , Working group on tuberculosis. Consensus statement on childhood tuberculosis. Indian Pediatrics2010;47(1):41‐55. ">IAP 2010</a>) recommends thrice‐weekly, intermittent DOTS in children at a higher dose; but fails to cite reliable evidence to support this change in recommendations. </p> <p>Current evidence‐based guidance from the WHO on the treatment of paediatric TB (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>; <a href="./references#CD007953-bbs2-0117" title="World Health Organization. Annex 1 ‐ Evidence summary tables. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010b</a>) recommends against using intermittent regimens (twice‐ or thrice‐weekly) in children with suspected or confirmed pulmonary TB or tuberculous peripheral lymphadenitis living in settings with a high HIV prevalence (or with confirmed HIV infection). The guidance suggests that thrice‐weekly regimens can be considered only during the continuation phase of treatment for children known to be HIV‐uninfected and living in settings with well‐established DOTS; thus only partially‐intermittent regimens are recommenced, and fully‐intermittent schedules (without initial daily treatment for two months) are not currently recommended for children with TB (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>). </p> <p>A Cochrane Review of fully‐intermittent dosing with drugs for treating TB in adults produced inconclusive results (<a href="./references#CD007953-bbs2-0092" title="MwandumbaHC , SquireSB . Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD000970] ">Mwandumba 2001</a>). In this review, we systematically evaluated the effects of intermittent versus daily dosing with anti‐TB drugs for TB in children with, and without, HIV infection, in order to inform policy and clinical practice. </p> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007953-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007953-sec-0036"></div> <p>To compare the efficacy and safety of intermittent, short‐course anti‐TB treatment regimens (twice‐ or thrice‐weekly) with daily short‐course anti‐TB treatment regimens in treating childhood TB. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007953-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007953-sec-0037"></div> <section id="CD007953-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007953-sec-0039"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) and quasi‐RCTs.</p> </section> <section id="CD007953-sec-0040"> <h4 class="title">Types of participants</h4> <section id="CD007953-sec-0041"> <h5 class="title">Inclusion criteria</h5> <p>Children aged 15 years or younger, diagnosed as having TB in category 1, 2, or 3 according to the WHO diagnostic categories (<a href="./appendices#CD007953-sec-0115">Appendix 1</a>). </p> </section> <section id="CD007953-sec-0042"> <h5 class="title">Exclusion criteria</h5> <p>Children diagnosed under category 4 (multiple‐drug resistant TB) by the WHO (<a href="./appendices#CD007953-sec-0115">Appendix 1</a>). </p> </section> </section> <section id="CD007953-sec-0043"> <h4 class="title">Types of interventions</h4> <section id="CD007953-sec-0044"> <h5 class="title">Interventions*</h5> <p> <ol id="CD007953-list-0001"> <li> <p>Twice‐weekly short‐course anti‐TB chemotherapy.</p> </li> <li> <p>Thrice‐weekly short‐course anti‐TB chemotherapy.</p> </li> </ol> </p> </section> <section id="CD007953-sec-0045"> <h5 class="title">Control*</h5> <p> <ol id="CD007953-list-0002"> <li> <p>Daily short‐course anti‐TB chemotherapy.</p> </li> </ol> </p> <p>* All regimens had to contain rifampicin for the intensive phase, which is the initial period when more intensive treatment is given. The total duration of treatment should ideally have been six months, but not have exceeded one year. We classified short course treatment regimens where daily dosing was used for the first two months as daily treatment, even if this was followed by intermittent treatment thereafter, since daily dosing in the intensive phase of treatment is considered critical for treatment success. </p> </section> </section> <section id="CD007953-sec-0046"> <h4 class="title">Types of outcome measures</h4> <section id="CD007953-sec-0047"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007953-list-0003"> <li> <p>Cure as defined by the trial authors and including the following:</p> </li> </ol> <ul id="CD007953-list-0004"> <li> <p>negative sputum test (if appropriate);</p> </li> <li> <p>weight gain;</p> </li> <li> <p>resolution of symptoms and signs within one month after completion of treatment. These may include, but are not confined to: </p> <ul id="CD007953-list-0005"> <li> <p>fever or cough,</p> </li> <li> <p>decrease in size of the lymph nodes, and</p> </li> <li> <p>resolution of the chest X‐ray findings.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD007953-sec-0048"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007953-list-0006"> <li> <p>Death from any cause during treatment or within one year after the completion of treatment.  </p> </li> <li> <p>Relapse: defined as re‐emergence of signs and symptoms of TB within 12 months after stopping treatment. </p> </li> <li> <p>Adherence to treatment: defined as the proportion of children who are not defaulters (a defaulter being a child whose treatment was interrupted for two consecutive months or more). </p> </li> </ol> </p> <section id="CD007953-sec-0049"> <h6 class="title">Adverse effects</h6> <p> <ol id="CD007953-list-0007"> <li> <p>Serious adverse effects: as defined by the trial authors and based on clinical or laboratory findings, or both. </p> </li> <li> <p>Treatment‐limiting adverse events: adverse effects during treatment requiring interruption or alteration of the treatment regimen. </p> </li> <li> <p>Other adverse effects: including skin rash, nausea or vomiting, diarrhoea, epigastric pain, fatigue or malaise, dizziness, headache, fever or chills, arthralgia, peripheral neuropathy, anorexia or weight loss, insomnia, and pruritis. </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD007953-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant trials, regardless of language or publication status (published, unpublished, or ongoing). </p> <section id="CD007953-sec-0051"> <h4 class="title">Electronic searches</h4> <section id="CD007953-sec-0052"> <h5 class="title">Databases</h5> <p>Vittoria Lutje (VL), the Information Specialist of the Cochrane Infectious Diseases Group (CIDG) editorial base searched the following databases: the CIDG Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in <i>The Cochrane Library</i> (Issue 5, 2013); MEDLINE; EMBASE; and LILACS, up to 30 May 2013 using the search terms detailed in <a href="./appendices#CD007953-sec-0116">Appendix 2</a>. </p> <p>In addition, on 28 May 2013 we searched the website of the Indian Medlars Center (IndMED; <a href="http://indmed.nic.in/" target="_blank">http://indmed.nic.in/</a>) and the South Asian Database of Controlled Clinical Trials (<a href="http://www.cochrane-sadcct.org/" target="_blank">http://www.cochrane‐sadcct.org/</a> ) using 'tuberculosis' and 'isoniazid' as search terms, to identify relevant trials from journals that may not be indexed in the databases named above. </p> </section> <section id="CD007953-sec-0053"> <h5 class="title">Prospective clinical trials registries</h5> <p>On 30 May 2013, VL updated searches of the metaRegister of Controlled Trials (mRCT) and the search portal of the WHO International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>) for ongoing trials. </p> </section> <section id="CD007953-sec-0054"> <h5 class="title">Conference proceedings</h5> <p>In May 2013 we updated searches of proceedings from relevant conferences based on their availability (see <a href="./appendices#CD007953-sec-0118">Appendix 3</a>). </p> </section> </section> <section id="CD007953-sec-0055"> <h4 class="title">Searching other resources</h4> <section id="CD007953-sec-0056"> <h5 class="title">Researchers and organizations</h5> <p>We contacted researchers in the field to identify additional trials that might be eligible for inclusion. We also contacted relevant organizations, including the WHO, the Prevention of Tuberculosis Trials Consortium (TBTC), the International Union Against TB &amp; Lung Disease, and the Global Partnership to Stop TB, for published, unpublished, and ongoing trials. </p> </section> <section id="CD007953-sec-0057"> <h5 class="title">Reference lists</h5> <p>In addition we checked the reference lists of all trials identified by the above methods.</p> </section> </section> </section> <section id="CD007953-sec-0058"> <h3 class="title" id="CD007953-sec-0058">Data collection and analysis</h3> <section id="CD007953-sec-0059"> <h4 class="title">Selection of studies</h4> <p>All review authors independently screened the citations and abstracts obtained by the searches to identify potentially eligible trials. We obtained the full articles for potentially eligible trials and independently evaluated them for inclusion. We excluded trials that recruited adults and children unless subgroup data for children were available from the trial report or from the trial authors. Disagreements were resolved by contacting the authors for clarification if needed, or by consensus. We documented the process of selection of trials in a flow diagram. The reasons for excluding studies are in the <a href="./references#CD007953-sec-0135" title="">Characteristics of excluded studies</a> section. </p> </section> <section id="CD007953-sec-0060"> <h4 class="title">Data extraction and management</h4> <p>Using pre‐tested data extraction forms, all review authors independently extracted data from the included trials, including the number of patients randomized and the number for which outcome(s) were measured. We extracted the number of events and the number of patients in each treatment arm for dichotomous outcomes, and arithmetic means and standard deviations together with the number of patients in each group for continuous outcomes. For cluster‐RCTs, we extracted the number of clusters, average cluster size, unit of randomization, adjustment for clustering or other covariate in the statistical analysis, and estimates of the intra‐cluster correlation coefficient (ICC) for each outcome. Where results were adjusted for clustering, we extracted the point estimate with 95% confidence intervals (CIs); otherwise, we extracted the data as for individually randomized trials. We resolved any inadequacies or discrepancies by discussion, and if required by contacting the trial authors. </p> </section> <section id="CD007953-sec-0061"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>All review authors independently assessed the risk of bias in the included trial reports. We assessed the six standard components: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other biases. For each of these components we assigned a judgment regarding the risk of bias as 'yes', 'no', or 'unclear' (<a href="./references#CD007953-bbs2-0071" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). Where necessary, we attempted to contact the trial authors for clarifications if any components were unclear or not stated in the report. We recorded the results in the standard tables in <a href="./references#CD007953-bbs2-0096" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">Review Manager (RevMan) 5.1</a>, and summarized the assessments in figures. </p> </section> <section id="CD007953-sec-0062"> <h4 class="title">Measures of treatment effect</h4> <p>Soumik Kalita (SK) and Winsley Rose (WR) entered data into standard tables in <a href="./references#CD007953-bbs2-0096" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">Review Manager (RevMan) 5.1</a>. Anuradha Bose (AB) and Prathap Tharyan (PT) independently checked all data. PT also performed additional data extraction and entry, which was checked by the other review authors. For dichotomous outcomes, we compared risk ratios and their 95% CIs. </p> </section> <section id="CD007953-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <p>For cluster‐RCTs, we combined the adjusted measures of effect with those from parallel group trials in meta‐analysis if the results were adjusted for clustering, using the generic inverse variance approach (<a href="./references#CD007953-bbs2-0060" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Chichester: John Wiley &amp; Sons, Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). If results were not adjusted for clustering, we attempted to adjust the results for clustering, by multiplying the standard errors of the estimates by the square root of the design effect where the design effect is calculated as D<sub>Eff</sub> = 1 + (M ‐ 1) ICC, where M is the average cluster size and ICC is the intra‐cluster correlation. If the results were not adjusted for clustering, we extracted data as for parallel‐group RCTs and combined them in the meta‐analysis with data from other parallel group randomized trials; but, if possible, evaluated their inclusion in a sensitivity analysis. </p> </section> <section id="CD007953-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain missing data from trial authors. We conducted an intention‐to‐treat analysis in trials with no loss to follow‐up and complete‐case analysis for trials with incomplete follow‐up, except for the primary outcome of cure, where we considered losses to follow‐up before symptom resolution not cured. We did not make any assumptions for the secondary outcomes or for adverse events, due to difficulties in making valid assumptions about those lost to follow‐up, apart from what was reported in the trials. </p> </section> <section id="CD007953-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between trials by examining forest plots for inconsistency in the direction or magnitude of the effect estimates, with non‐overlapping CIs. We used the Chi<sup>2</sup> test for heterogeneity with a 10% level of significance to detect inconsistency in trial results that exceeded chance, and the I<sup>2</sup> statistic to denote the percentage of inconsistency in results due to inter‐trial variability that exceeded random‐error (<a href="./references#CD007953-bbs2-0070" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> <p>In general, we interpreted an I<sup>2</sup> value of 50% or greater to denote significant heterogeneity (<a href="./references#CD007953-bbs2-0070" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), though we acknowledge that this cut‐off is arbitrary. Therefore we interpreted I<sup>2</sup> values between 0% to 40% as possibly unimportant, 30% to 60% as possibly significant, 50% to 90% as possibly substantial, and 75% to 100% as possibly considerable; depending on whether the inconsistency in results was due to differences in the direction of effect estimates between trials, rather than due to differences in the magnitude of effect estimates favouring an intervention; as well as the strength of the evidence for heterogeneity from the P value for the Chi<sup>2</sup> test for heterogeneity (<a href="./references#CD007953-bbs2-0060" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Chichester: John Wiley &amp; Sons, Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD007953-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had included at least 10 trials in a meta‐analysis, we would have considered assessing the likelihood of publication bias by examining the funnel plot for asymmetry due to small study effects. </p> </section> <section id="CD007953-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We stratified analyses by trial characteristics for the primary outcome (twice‐weekly and thrice‐weekly); or fully intermittent versus partially intermittent, and duration of interventions. We synthesized comparable data using the Mantel‐Haenszel method to derive pooled, weighted risk ratios in fixed‐effect meta‐analyses. We used the random‐effects model for data synthesis when we identified significant heterogeneity (see above) which could not be explained by subgroup analyses (see below). If I<sup>2</sup> values revealed substantial inter‐trial variability in effect estimates in excess of chance that we thought were not due to variations in clinical or methodological attributes, we suggested caution in interpreting the pooled estimates. If substantial heterogeneity was unexplained, we presented the results of the trials in a forest plot, without summating their effect estimates. </p> </section> <section id="CD007953-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The limited number of trials precluded subgroup analysis. In future editions with more trials, we would consider subgroups on the stratified analysis for fully intermittent chemotherapy (twice‐ or thrice‐weekly) and daily short‐course chemotherapy by age (younger or older than 4); HIV status; and previous TB treatment. </p> </section> <section id="CD007953-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We attempted to conduct sensitivity analyses to investigate the robustness of the results to the various risk of bias components and the intention‐to‐treat sample versus completers, as well as to assumptions made in data analyses (such as when dealing with data from cluster‐RCTs). </p> <section id="CD007953-sec-0070"> <h5 class="title"><i>Summarising and interpreting results</i> </h5> <p>We used the GRADE approach to interpret findings (<a href="./references#CD007953-bbs2-0100" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Hanbook for Systematic Reviews of Intervention. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. The Cochrane Collaboration. ">Schunemann 2008</a>) and used GRADE Profiler (<a href="./references#CD007953-bbs2-0067" title="Jan Brozek, Andrew Oxman, Holger Schünemann. GRADE Profiler. Version 3.6 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2013. ">GRADE 2013</a>) to import data from <a href="./references#CD007953-bbs2-0096" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">Review Manager (RevMan) 5.1</a> to create 'Summary of findings' tables for each comparison included in this review. These tables provide information concerning the overall quality of the evidence from the trials, the magnitude of effect of the interventions examined, and the sum of available data on the primary outcome and selected secondary outcomes.The GRADE approach integrates evaluations regarding study limitations; unexplained inconsistency in the results; indirectness (how representative of clinical practice the populations studied were; the deviations from accepted practice in the way interventions and comparisons were given; the choice of outcomes as representative of those considered important to clinical decision‐making; and the methods used in assessing these outcomes); imprecision in the estimates (in terms of statistical significance as well as clinical importance); and the likelihood that publication bias affected the estimates. </p> <p>The outcomes we included in these tables, which were rated important or critically important to clinical decision‐making, were: </p> <p> <ol id="CD007953-list-0008"> <li> <p>Cure</p> </li> <li> <p>Death due to any cause</p> </li> <li> <p>Relapse</p> </li> <li> <p>Adherence</p> </li> <li> <p>Treatment‐limiting adverse events.</p> </li> </ol> </p> <p>We used this summary to guide our conclusions and recommendations.</p> <p>The GRADE Working Group (<a href="./references#CD007953-bbs2-0100" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Hanbook for Systematic Reviews of Intervention. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. The Cochrane Collaboration. ">Schunemann 2008</a>) considers<i>high quality evidence</i> to denote that the effect estimate is likely to reflect the effects obtained in clinical practice and that further research is very unlikely to change our confidence in the estimate of effect. <i>Moderate quality evidence</i> denotes that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <i>Low quality evidence</i> indicates that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<i>Very low quality evidence</i> denotes a serious lack of confidence in the effect estimates. </p> <p>We standardized terminology to refect these grades of quality in this review;</p> <p> <ul id="CD007953-list-0009"> <li> <p><i>High quality evidence</i> is denoted by statements to this effect. </p> </li> <li> <p>We used the term "probably" to denote the effects of treatment or control when evidence was of <i>moderate quality evidence.</i> </p> </li> <li> <p>We used the word "may" to describe the likely effects when evidence was of <i>low quality</i>. </p> </li> <li> <p><i>Very low overall quality</i> assessments indicate considerable doubts of the internal or external validity of the effect estimate. </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007953-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007953-sec-0071"></div> <section id="CD007953-sec-0072"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD007953-sec-0134" title="">Characteristics of included studies</a> and <a href="./references#CD007953-sec-0135" title="">Characteristics of excluded studies</a>. </p> <section id="CD007953-sec-0073"> <h4 class="title">Results of the search</h4> <p>Our search retrieved 82 records, of which we considered the abstracts of only 44 relevant. We scrutinised these abstracts, obtained and assessed 12 full text reports, and selected four trials for inclusion. See <a href="#CD007953-fig-0001">Figure 1</a> for a flow diagram of the selection process. </p> <div class="figure" id="CD007953-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of the selection process." data-id="CD007953-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of the selection process.</p> </div> </div> </div> <p>No trials currently await classification and we are not aware of any ongoing trials.</p> </section> <section id="CD007953-sec-0074"> <h4 class="title">Included studies</h4> <p>We included four RCTs published between 1996 and 2000 that compared various regimens of daily versus intermittent therapy of anti‐TB chemotherapy in 563 children (465 of whom were evaluable). One trial randomized children by households (<a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>) but did not report the proportions in each arm that were cluster‐randomized and individually randomized. In the other three trials, the unit of randomization was the individual. We have described the four trials in detail in <a href="./references#CD007953-sec-0134" title="">Characteristics of included studies</a> and have summarized them below. </p> <section id="CD007953-sec-0075"> <h5 class="title">Location</h5> <p>Two trials were conducted in India (<a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a>; <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a>); one in South Africa (<a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>), and one in Turkey (<a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a>). </p> </section> <section id="CD007953-sec-0076"> <h5 class="title">Age</h5> <p>All four trials included children aged five months to 15 years. <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> recruited children aged five months to 13 years; <a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a> recruited children aged one to 15 years; <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> recruited children &lt; 14 years of age; and <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> randomized children aged one to 12 years old. </p> </section> <section id="CD007953-sec-0077"> <h5 class="title">Diagnosis of TB</h5> <p>All trials used a combination of clinical and radiological criteria (parenchymal or mediastinal lymph nodes in chest radiograph) to diagnose childhood TB; in addition <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> used epidemiological criteria (contact with adult TB) and immunological criteria (tuberculin skin test (TST) response). <a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a> used explicit criteria to diagnose children with TB lymphadenopathy, pulmonary TB, and disseminated TB; <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> reported detailed criteria used to diagnose 'most probable' and 'probable TB', with a course of antibiotics given to the latter and repeat chest X‐ray after two weeks of treatment, prior to inclusion and treatment of those with unresolved lung lesions. <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> used WHO criteria, current at the time of the trial, to diagnose suspected and confirmed cases of intra‐thoracic TB (see <a href="./references#CD007953-sec-0134" title="">Characteristics of included studies</a>). </p> </section> <section id="CD007953-sec-0078"> <h5 class="title">Comparisons</h5> <p>The four included trials compared four different intermittent short‐course versus daily anti‐TB treatment regimens. </p> <section id="CD007953-sec-0079"> <h6 class="title">1. Partially‐intermittent (daily two weeks, intermittent 8.5 months) versus daily treatment (nine to 12 months) regimen </h6> <p><a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> used streptomycin in both treatment arms, and used different drugs and durations of treatment in the intermittent and daily treatment arms (Intermittent‐short course chemotherapy group: streptomycin, rifampicin, and isoniazid (INH) daily for two weeks, followed by INH and rifampicin twice‐weekly for eight and a half months versus conventional chemotherapy group: daily streptomycin for 40 days, rifampicin for nine months and INH for 12 months). While both arms had a daily treatment component, we classified this trial as a comparison of intermittent versus daily treatment, since the intermittent treatment arm used daily treatment only for two weeks of initial treatment. </p> </section> <section id="CD007953-sec-0080"> <h6 class="title">2. Fully‐intermittent (six months) versus daily treatment plus intermittent treatment (daily two months, intermittent four months) regimen </h6> <p><a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a> compared a fully‐intermittent twice‐weekly regimen (INH, rifampicin, and pyrazinamide given twice‐weekly for two months followed by INH and rifampicin twice‐weekly for four months versus a partially‐intermittent regimen with daily dosing in the intensive phase (INH, rifampicin, and pyrazinamide given daily for two months followed by INH and rifampicin twice‐weekly for four months). Though both arms used intermittent treatments, we considered this as a comparison of intermittent treatment versus daily treatment since daily treatment was used throughout the two‐month intensive treatment phase, This trial also permits an evaluation of intermittent treatment regimens with and without two‐months of daily treatment in the intensive treatment phase. </p> </section> <section id="CD007953-sec-0081"> <h6 class="title">3. Fully intermittent (six months) versus daily treatment (nine months) regimen</h6> <p><a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> compared a fully‐intermittent regimen using thrice‐weekly and twice‐weekly dosing (INH, rifampicin, and pyrazinamide thrice‐weekly for two months, followed by INH and rifampicin twice‐weekly for four months) versus a longer nine month daily regimen (INH and rifampicin daily for nine months). </p> </section> <section id="CD007953-sec-0082"> <h6 class="title">4. Fully intermittent (six months) versus daily treatment (six months) regimen</h6> <p><a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>) compared a twice‐weekly fully intermittent six‐month regimen of INH, rifampicin, and pyrazinamide with a daily regimen of INH, rifampicin, and pyrazinamide (five days a week) for six months. </p> </section> </section> <section id="CD007953-sec-0083"> <h5 class="title">Drug doses</h5> <p>The doses used in the intermittent arms of the four trial were comparable with currently recommended dosing for intermittent regimens. </p> </section> <section id="CD007953-sec-0084"> <h5 class="title">Outcomes</h5> <p>Childhood TB can affect several organs in the body, and response to therapy is defined according to the organ involved, in addition to general systemic signs and symptoms. The four trials used different definitions for the outcomes examined. </p> <section id="CD007953-sec-0085"> <h6 class="title">Primary outcome</h6> <section id="CD007953-sec-0086"> <p><b>Cure</b></p> <p><a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> used clinical and radiological assessments and weight gain to monitor children for clinical improvement. <a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a> provided explicit criteria to define general improvement (afebrile, improved appetite, weight gain); and for marked, moderate, and poor improvement for pulmonary TB, with poor improvement defined as no significant general improvement, no radiological clearance, and increase in the size of pulmonary lesions or the appearance of new lesions. <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> monitored resolution of radiological lesions to evaluate treatment response and we used the proportions with complete resolution as well as those with general improvement but with residual lesions to define cure in this review. </p> <p><a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> assessed response to treatment based on a composite score on four domains (parental assessment, clinical assessment, weight gain, and chest radiograph), with each scored from ‐1 (worse);  0 (no better);  +1 (better); + 2 (much better). The combined scores ranged from ‐4 to +8. Trial authors considered any patient with a score of four or more as better or improved on all four domains; and those scoring eight as free of clinical and radiological evidence of TB. Assessments were at 3, 6, 12, and 18 to 30 months. For the 12‐month, and 18‐ to 30‐month assessments, parental ratings were omitted; therefore the composite scores ranged from ‐3 to +6. Thus, the trial authors considered anyone with a score of three or more as improved at 12 months or later. The outcomes in those assessed at the follow‐up time points were presented as median scores (with ranges), but the proportions in the treatment groups considered to be responders were not reported. </p> <p>However, the authors reported that at six months, 163 of 206 randomized evaluable children were assessed for treatment response (77%); of whom 70/89 (79%) were in the arm allocated twice‐weekly intermittent treatment for six months and 93/117 (79%) were in the six month daily‐treatment arm (P = 0.40). The median (range) of combined outcome scores were 6 (5 to 7) in the intermittent arm and 6 (5 to 7) in the daily treatment arm at this time point (six months‐ the closest time point to  our review’s time point of one month after completion of treatment). At 18‐ to 30‐month assessments, 71 (75%) in the intermittent treatment arm and 74 (63%) in the daily treatment arm were scored for treatment response (P = 0.73) and the median scores were 4 out of a possible 6 (range 3 to 5) in both arms (P = 0.949). Thus the six month outcomes were maintained at 18 to 30 month assessments. We interpreted the proportions 'cured' in our review as all those who scored four or more at six months. Since the lower limit of the score ranged from five to seven at six months, we interpreted this to mean that all children assessed fulfilled our description of 'cured'. The first author of <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> confirmed these interpretations in personal discussions with PT and in subsequent e‐mail communications. </p> </section> </section> <section id="CD007953-sec-0087"> <h6 class="title">Secondary outcomes</h6> <p>All trials reported relapse and adherence, and serious adverse events that were also defined and assessed in different ways (see <a href="./references#CD007953-sec-0134" title="">Characteristics of included studies</a>). </p> <p>Two trials reported deaths (<a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a>; <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a>), and we assumed that no deaths occurred in the other two included trials based on the number of children that completed follow‐up. </p> <p>The included trials reported non‐serious adverse events poorly and it was unclear if they were systematically ascertained. </p> </section> </section> </section> <section id="CD007953-sec-0088"> <h4 class="title">Excluded studies</h4> <p>We have described the 44 excluded trials in the <a href="./references#CD007953-sec-0135" title="">Characteristics of excluded studies</a> section, with the reasons for their exclusion. Thirteen were RCTs, of which 10 did not fulfil inclusion criteria. Three trials (<a href="./references#CD007953-bbs2-0044" title="Tuberculosis Research Centre. A controlled clinical trial of oral short‐course regimens in the treatment of sputum‐positive pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease1997;1(6):509‐17. ">TRC 1997</a>; <a href="./references#CD007953-bbs2-0025" title="JindaniA , NunnAJ , EnarsonDA . Two 8‐month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet2004;364(9441):1244‐51. ">Jindani 2004</a>; <a href="./references#CD007953-bbs2-0024" title="JawaharMS , RajaramK , SivasubramanianS , ParamasivanCN , ChandrasekarK , KamaludeenMN , et al. Treatment of lymph node tuberculosis‐‐a randomized clinical trial of two 6‐month regimens. Tropical Medicine &amp; International Health2005;10(11):1090‐8. [PUBMED: 16262733] ">Jawahar 2005</a>) included adults and children, but we were unable to obtain disaggregated data for children from the reports or the authors. We have discussed their exclusion under <a href="#CD007953-sec-0107">Potential biases in the review process</a>. </p> </section> </section> <section id="CD007953-sec-0089"> <h3 class="title">Risk of bias in included studies</h3> <p>None of the included trials were free from risk of bias for many of the domains assessed (see <a href="#CD007953-fig-0002">Figure 2</a> and <a href="#CD007953-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD007953-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included trials." data-id="CD007953-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD007953-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included trial." data-id="CD007953-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included trial. </p> </div> </div> </div> <section id="CD007953-sec-0090"> <h4 class="title">Allocation</h4> <p><a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> was at unclear risk of bias for random sequence generation, but at high risk of bias due to inadequate allocation concealment arising from obtaining informed consent after randomization. This resulted in differential exclusion rates in the intervention arms. Of 153 children randomized to intermittent treatment, the trial only included 95 (62%) after exclusions; of 161 children randomized to daily treatment, the trial only included 118 (73%) after exclusions; and this difference was statistically significant (P &lt; 0.05). The other trials were at unclear risk of selection bias due to lack of information in the trial reports on the methods. </p> </section> <section id="CD007953-sec-0091"> <h4 class="title">Blinding</h4> <p><a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> and <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> were at unclear risk of detection bias due to the open‐label design of both trials, the lack of reporting of the use of independent outcome assessors in the former trial, and the difficulty in blinding the composite outcome used in the latter trial. </p> </section> <section id="CD007953-sec-0092"> <h4 class="title">Incomplete outcome data</h4> <p>All trials were free of attrition risk of bias.</p> </section> <section id="CD007953-sec-0093"> <h4 class="title">Selective reporting</h4> <p>None of the trials were prospectively registered or had a protocol that was available in the public domain. However, we did not detect any evidence of selective reporting. </p> </section> <section id="CD007953-sec-0094"> <h4 class="title">Other potential sources of bias</h4> <p>It was unclear in <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> whether the lack of adjusting for clustering resulted in falsely imprecise effect estimates, as the trial authors did not report the proportions of children in each arm that were randomized by household, or as individuals. The first author indicated via correspondence and personal discussions that a low number of children were randomized by household, but the exact proportions in each intervention arm were not available. </p> </section> </section> <section id="CD007953-sec-0095"> <h3 class="title" id="CD007953-sec-0095">Effects of interventions</h3> <p>See: <a href="./full#CD007953-tbl-0001"><b>Summary of findings for the main comparison</b> Intermittent short‐course anti‐TB regimens compared to daily anti‐TB regimens for treating TB in children</a> </p> <section id="CD007953-sec-0096"> <h4 class="title">Cure</h4> <p>Intermittent and daily treatments cured similar proportions of children, in intention to treat analysis, where those lost to follow‐up before being judged treatment responders, and those who required extended treatment after the allocated treatment duration were considered not cured (RR 1.01, 95% CI 0.94 to 1.10, four trials, 465 children; <a href="./references#CD007953-fig-0006" title="">Analysis 1.1</a>; <a href="#CD007953-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD007953-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot: 1. Intermittent versus daily regimens, Outcome 1.1 Cure (as defined by clinical and radiological improvement): Intention to treat." data-id="CD007953-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot: 1. Intermittent versus daily regimens, Outcome 1.1 Cure (as defined by clinical and radiological improvement): Intention to treat. </p> </div> </div> </div> <p>In per‐protocol sensitivity analysis of evaluable children judged cured (where drop‐outs were not included), the pooled estimate again did not significantly differ between daily treatment versus intermittent treatments (four trials, 441 children; <a href="./references#CD007953-fig-0007" title="">Analysis 1.2</a>). In additional sensitivity analysis, excluding <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> which was at high risk of selection bias, and also had data unadjusted for clustering, the pooled effect estimates continued to show no significant difference between intermittent and daily treatment regimens for children cured (RR 1.02; 95% CI 0.93 to 1.12; three trials, 352 children). </p> </section> <section id="CD007953-sec-0097"> <h4 class="title">Deaths due to any cause</h4> <p>Intermitttent treatments did not differ from daily treatments in the proportions who died due to any cause (four trials, 460 children; <a href="./references#CD007953-fig-0008" title="">Analysis 1.3</a>), though only two trials (<a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a>; <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a>) reported any mortality due to TB. In the latter trial, one additional death that was not thought to be TB‐related was reported, but allocation to intermittent or daily treatment was not stated. </p> </section> <section id="CD007953-sec-0098"> <h4 class="title">Relapse</h4> <p>Only one trial reported one confirmed relapse among 449 evaluated children (with intermittent treatment) over 24 months of follow‐up (<a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>; <a href="./references#CD007953-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD007953-sec-0099"> <h4 class="title">Adherence to treatment</h4> <p>Adherence rates (defined and assessed in different ways) did not differ significantly with intermittent treatment or with daily treatment (four trials, 458 children; <a href="./references#CD007953-fig-0010" title="">Analysis 1.5</a>; <a href="#CD007953-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD007953-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot: 1. Intermittent versus daily regimens, Outcome 1.5 Adherence to treatment." data-id="CD007953-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot: 1. Intermittent versus daily regimens, Outcome 1.5 Adherence to treatment.</p> </div> </div> </div> </section> <section id="CD007953-sec-0100"> <h4 class="title">Adverse events</h4> <p>None of the participants in the four trials were reported to have developed serious adverse events. Adverse events requiring interruption of treatment were not significantly different with both schedules (four trials, 441 children; <a href="./references#CD007953-fig-0011" title="">Analysis 1.6</a>). These events were transient hepatic toxicity in three children in two trials that required alterations in trial medication till resolution of symptoms and liver functions tests had normalized (Ramachandran (India) 1998 and Te Water Naude (South Africa) 2000). Among other adverse events, two trials reported transient episodes of vomiting and mild joint pains in the initial period. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007953-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007953-sec-0101"></div> <section id="CD007953-sec-0102"> <h3 class="title" id="CD007953-sec-0102">Summary of main results</h3> <p>Four RCTs that were not free of study limitations compared different schedules of intermittent short‐course anti‐TB treatments versus daily treatments in 563 (465 evaluable) children aged five months to 15 years, who were not known to have drug resistance to anti‐TB drugs, The combination of drugs, and the duration of intermittent and daily treatments differed between trials, and none used drug combinations and schedules currently recommended for childhood TB. </p> <p>Intermittent twice‐weekly, short‐course treatments and the daily treatment regimens cured 84% of the children treated with each regimen, but the risk of bias in the trials, the non‐standard treatments used, and imprecision in the estimate of cure due to the small number of children evaluated with these regimens limit our confidence in this estimate (<a href="./full#CD007953-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Deaths due to any cause (1.3% versus 0.8%), and adherence to treatment were probably little different (87% versus 84%) with intermittent as with daily anti‐TB regimes, while relapses (only one in the four trials) may also be infrequent with both regimens. </p> <p>Intermittent and daily treatments did not differ significantly in rates of adverse events requiring interruption of treatment (0.6% versus 1.5%). No child developed serious adverse events in the four trials, and other adverse events were infrequent and transient. </p> </section> <section id="CD007953-sec-0103"> <h3 class="title" id="CD007953-sec-0103">Overall completeness and applicability of evidence</h3> <section id="CD007953-sec-0104"> <h4 class="title">Completeness of the evidence</h4> <p>We believe that we have identified all RCTs that fulfilled the inclusion and exclusion criteria used in this review. The fact that we found only four RCTs addressing the review question is evidence of the lack of importance given to research specific to children with TB, in spite of the importance of childhood TB to global TB control. Important gaps remain in the evidence base for treating childhood TB. Notably, we did not find any RCTs comparing the commonly used thrice‐weekly treatment regimens with daily treatment. None of the trials reported the HIV‐status of the children randomized. </p> <p>These lacune in the body of evidence limit our ability to draw conclusions regarding the effects of intermittent dosing versus daily short‐course anti‐TB treatment, in HIV‐negative or HIV‐positive children with TB. </p> </section> <section id="CD007953-sec-0105"> <h4 class="title">Applicability of the evidence</h4> <p>Although the included trials used different definitions for the diagnosis of childhood TB, they concur with current methods used in clinical practice to diagnose TB in children. All trials excluded children with primary complex and included the spectrum of childhood TB covered in the WHO Classification 1, 2, or 3, except <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> which excluded children with extrapulmonary TB. The trials were conducted in high TB‐burden low‐ and middle‐income counties, where most children with TB live, and recruited children as young as five months of age to 15 years of age. The doses of anti‐TB drugs used were comparable to currently recommended doses for anti‐TB drugs.The treatments in the trials were provided by DOTS, except <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> where supervision of treatment was unclear from the trial report. </p> <p>However, the treatment regimens used in all of the trials were not similar to current recommendations for the treatment of childhood TB (<a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>; <a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>). </p> <p><a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> used streptomycin in the intensive phase of the intermittent regimen and the daily regimen though this is recommended in current guidance only for children with multi‐drug resistant TB susceptible to streptomycin, and not as a first line treatment for children with pulmonary TB or TB lymphadenitis (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>). In the intermittent‐treatment arm, the intensive phase was for only two weeks and the short‐course regimen in total lasted nine months, where INH and rifampicin were given. The daily treatment arm had streptomycin for 40 days, followed by INH and rifampicin for nine months and INH alone for another three months. </p> <p><a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a> included children with TB lymphadenitis, pulmonary TB and disseminated TB and used INH, rifampicin, and pyrazinamide in the two‐month intensive phase in the partially‐intermittent arm (daily treatment for the first two months) and the twice‐weekly fully‐intermittent arm. Current guidance (<a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>; <a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>) recommends the addition of ethambutol in the intensive phase for disseminated TB and severe forms of pulmonary TB. </p> <p><a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> used a combination of thrice‐weekly and twice‐weekly regimens in the intermittent treatment arm. In the intensive treatment phase, INH, rifampicin, and pyrazinamide were given thrice‐weekly for two months, followed by INH and rifampicin given twice‐weekly for four months of continuation treatment. The daily treatment was for nine months and did not include pyrazinamide in the intensive treatment period. </p> <p><a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> used pyrazinamide in the twice‐weekly and the daily treatment arms in the intensive as well as the continuation phases; while current guidance (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>) recommends pyrazinamide only in the intensive treatment phase. Ethambutol did not form part of the treatment regimens. </p> <p>Although not a stated outcome of this review, none of the included trials included estimates of resource costs and resource use or cost‐effectiveness of the intermittent versus daily regiments. Economic analytes derived from trials would have permitted better‐informed policies regarding the treatment of childhood TB. </p> </section> </section> <section id="CD007953-sec-0106"> <h3 class="title" id="CD007953-sec-0106">Quality of the evidence</h3> <p>We assessed the overall quality of the evidence using the GRADE approach (<a href="./references#CD007953-bbs2-0100" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Hanbook for Systematic Reviews of Intervention. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. The Cochrane Collaboration. ">Schunemann 2008</a>), that considers ‘quality’ to be a judgment of the extent to which we can be confident that the estimates of effect are correct. Evidence from a RCT is initially graded as high and downgraded by one or two levels on each of five domains after full consideration of: any limitations in the design of the studies, the directness (or applicability) of the evidence, the consistency and precision of the results, and the possibility of publication bias. A GRADE quality level of '<i>high</i> ' reflects confidence that the true effect lies close to that of the estimate of the effect for an outcome. A judgement of '<i>moderate</i> ' quality indicates that the true effect is likely to be close to the estimate of the effect, but acknowledges the possibility that it could be substantially different. '<i>Low</i> ' and '<i>very low</i>' quality evidence limit our confidence in the effect estimate (<a href="./references#CD007953-bbs2-0050" title="BalshemH ,  HelfandM ,  SchünemannHJ ,  OxmanAD ,  KunzR ,  BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>). </p> <p>The overall quality of the evidence for intermittent short‐course versus daily anti‐TB treatments from the four included trials was <i>very low</i> for all outcomes (<a href="./full#CD007953-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD007953-sec-0107"> <h3 class="title" id="CD007953-sec-0107">Potential biases in the review process</h3> <p>We used standard methods described in the Cochrane handbook for systematic reviews of interventions (<a href="./references#CD007953-bbs2-0072" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>), and also ensured compliance with the Cochrane standards for the conduct of new reviews of interventions (<a href="./references#CD007953-bbs2-0089" title="ChandlerJ , ChurchillR , HigginsJ , LassersonT , ToveyD . Methodological Expectations of Cochrane Intervention Reviews (MECIR). Methodological standards for the conduct of new Cochrane Intervention Reviews. Version 2.1, 8 December 2011Available from http://www.editorial‐unit.cochrane.org/sites/editorial‐unit.cochrane.org/files/uploads/MECIR_conduct_standards%202.1.pdf. ">MECIR 2011</a>). Since the review protocol was developed and published before the GRADE approach was introduced into Cochrane reviews, the choice of critical outcomes selected for the Summary of Findings tables were done after the protocol was published; but we evolved these during discussions and before extracting data from the included trials. </p> <p>We excluded three trials that met inclusion criteria for this review because data on children were not presented separately from that of adults, and we could not obtain data on children from the authors. <a href="./references#CD007953-bbs2-0044" title="Tuberculosis Research Centre. A controlled clinical trial of oral short‐course regimens in the treatment of sputum‐positive pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease1997;1(6):509‐17. ">TRC 1997</a> included participants aged &gt; 12 years, and included some children aged 12 to 15, though the exact number in each intervention arm was unclear from the trial report, and was not available from the trial authors. The trial evaluated ethambutol‐containing versus non‐ethambutol containing regimens and supervised versus partially or completely unsupervised treatment; hence this trial is not strictly relevant to this review. <a href="./references#CD007953-bbs2-0025" title="JindaniA , NunnAJ , EnarsonDA . Two 8‐month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet2004;364(9441):1244‐51. ">Jindani 2004</a> recruited participants aged 15 years to 65 years and the number of children aged 15 years was not available. This trial had two daily treatment arms where four drugs (ethambutol, INH, rifampicin, and pyrazinamide) were given for two months of intensive treatment; continuation was with rifampicin and INH for four months in one arm and with ethambutol and INH in the other given for six months. A third arm studied thrice‐weekly administration of ethambutol, INH, rifampicin, and pyrazinamide for two months followed by daily ethambutol and INH for six months, and hence these comparisons are also not relevant to this review, or to current practice. </p> <p><a href="./references#CD007953-bbs2-0024" title="JawaharMS , RajaramK , SivasubramanianS , ParamasivanCN , ChandrasekarK , KamaludeenMN , et al. Treatment of lymph node tuberculosis‐‐a randomized clinical trial of two 6‐month regimens. Tropical Medicine &amp; International Health2005;10(11):1090‐8. [PUBMED: 16262733] ">Jawahar 2005</a> randomly allocated 277 people in Madurai, South India (87 children &lt; 12 years of age) with biopsy confirmed lymph node TB to receive either a daily self‐administered 6‐month regimen of rifampicin and INH, or a twice‐weekly, directly observed, 6‐month regimen of rifampicin and INH; with pyrazinamide given for the first two months. Patients were followed up for 36 months after completing treatment. At 36 months, 94% of those treated with the daily regimen and 96% of those treated with the twice‐weekly intermittent regimen had a successful outcome. Although the drug combinations used in this trial are not the currently recommended combinations, the result of this trial in children and adults is consistent with the results in this review. </p> </section> <section id="CD007953-sec-0108"> <h3 class="title" id="CD007953-sec-0108">Agreements and disagreements with other studies or reviews</h3> <p>The current evidence‐based guidance from the WHO on the treatment of paediatric TB (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>; <a href="./references#CD007953-bbs2-0117" title="World Health Organization. Annex 1 ‐ Evidence summary tables. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010b</a>) recommends only partially‐intermittent thrice‐weekly regimens (daily treatment for two months and intermittent treatment only in the continuation phase of four months) for children known to be HIV‐uninfected, living in settings with low HIV prevalence and with well‐established DOTS programmes. The revised guidelines of the Indian Academy of Pediatrics (<a href="./references#CD007953-bbs2-0075" title="Indian Academy of Pediatric(IAP) , Working group on tuberculosis. Consensus statement on childhood tuberculosis. Indian Pediatrics2010;47(1):41‐55. ">IAP 2010</a>) also recommends thrice‐weekly anti‐TB treatment. The National TB Control Programme of India (<a href="./references#CD007953-bbs2-0097" title="Revised National Tuberculosis Control Programme. National guidelines on diagnosis and treatment of pediatric tuberculosis. http://tbcindia.nic.in/documents.html. Directorate General of Health Services. Ministry of Health and Family Welfare, (accessed 1 November 2012). ">RNTCP 2012</a>) recommends thrice‐weekly treatment in the intensive treatment and continuation phases. However, we did not find any RCTs of thrice‐weekly fully‐intermittent or partially‐intermittent treatment regimens versus daily or twice‐weekly, intermittent anti‐TB treatment regimens. </p> <p>The WHO (<a href="./references#CD007953-bbs2-0117" title="World Health Organization. Annex 1 ‐ Evidence summary tables. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010b</a>) recommends only partially‐intermittent thrice weekly regimens, and only in HIV‐negative children with TB from settings where effective DOTS can be assured; and does not recommend twice‐weekly intermittent regimens (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>). This recommendation was influenced by a meta‐analysis (<a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a>) that was published while this review was in progress. This meta‐analysis also included only the four trials included in our review. The results of the pooled estimates of effect in <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> indicated that children receiving twice‐weekly intermittent therapy were less likely to be cured than those receiving daily therapy (per protocol analysis: OR 0.27, 96% CI 0.15 to 0.51; four trials, 466 children), though the results were not statistically significant in intention‐to treat analysis (OR 0.66; 95% CI 0.23 to 1.84). Our review did not find any significant differences in intention to treat and per protocol analysis of cure rates between intermittent and daily therapy in the same trials. The reasons for the differences in the results of our review and that of <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> are: </p> <p> <ol id="CD007953-list-0010"> <li> <p><i>Choice of effect measure</i>: <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> used odds ratios as the effect measure while we chose risk ratios to express effects, since risks ratios are intuitively better understood by clinicians; and also because when event rates are common (risk is more than ˜ 20%), odds ratios and risk ratios differ in their magnitude and precision (with odds ratios often over‐estimating effects); this may alter the pooled effect estimates (<a href="./references#CD007953-bbs2-0060" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Chichester: John Wiley &amp; Sons, Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </li> <li> <p><i>Interpretation of primary data</i>: There were two important differences in the interpretation of primary data from the same trials used for meta‐analysis in our review and that of <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a>. </p> <ol id="CD007953-list-0011"> <li> <p>We defined cure as resolution of symptoms and signs within one month after completion of treatment and hence did not include those children in <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> who required extended treatment after the allocated treatment as among those cured in our intention‐to‐treat and in per‐protocol analyses. This is in conformity with internationally accepted definitions (<a href="./references#CD007953-bbs2-0115" title="World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. http://libdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf (accessed 19 November 2008). ">WHO 2006b</a>) where anyone requiring treatment at the end of therapy (if less than five months) or after at least five months of therapy, is considered a treatment failure. In the primary per‐protocol analysis in <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a>, the data for the nine children who required extended treatment were included among those cured. <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> also reported that when only those in <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> who did not need extended regimen were considered cured in sensitivity analysis, the pooled analysis did not reveal statistically significant differences between the two arms (OR 0.53, 95% CI 0.23 to 1.21). </p> </li> <li> <p><a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a> reported under treatment outcome in the results section that, "The number completing therapy on schedule was 199, with 85 (96%) in the intermittent group and 114 (97%) in the daily group (P = 0.59)". <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> interpreted this sentence to mean cure rates and were used in their data synthesis, while we believe that this sentence indicates treatment‐completion rates. The next two sentences in the trial report refer to the actual treatment outcome scores and state that "The treatment outcome scores for the two regimens scored at 3, 6, 12 and 18 to 30 months after starting treatment, and the numbers of children attending for evaluation of each of the time points are summarized in Table 4. No difference was found in the 2 groups." We used the data for the evaluation at six months in Table 4 of the report to derive the proportions cured, as described fully in the sub‐section on outcomes in the <a href="./full#CD007953-sec-0071">Results</a> section under <a href="#CD007953-sec-0074">Included studies</a> of this review. Our analysis of the data from this trial also demonstrates no significant difference between intervention arms, as does the trial report. However, in <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a>, the effect estimates for the proportions cured in this study indicated a benefit for daily treatment over twice‐weekly intermittent treatment (OR 0.30, 95% CI 0.09 to 0.98). This estimate is not in agreement with the conclusion in the trial report, or with our interpretation of the data for the proportions cured in the trial. The first author of this trial subsequently confirmed that the data used in <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> for cure rates were actually treatment completion rates, and also confirmed our interpretation of cure rates from the trial. </p> </li> </ol> </li> <li> <p><i>Discrepancies between intention to treat and per‐protocol analyses:</i><a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> opted to present the statistically significant results of per‐protocol analyses over the statistically non‐significant results obtained with intention‐to‐treat analyses in framing conclusions. When sensitivity analyses show that the overall result and conclusions are not affected, then the results of a review can be regarded with a higher degree of certainty; otherwise the results must be interpreted with caution (<a href="./references#CD007953-bbs2-0060" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Chichester: John Wiley &amp; Sons, Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). The results of our intention‐to‐treat analysis and the per‐protocol sensitivity analysis did not differ, and confirmed our conclusions. </p> </li> <li> <p><i>Linking overall quality of the evidence to the effect estimates in framing conclusions:</i> We used the GRADE approach to assess the overall quality of evidence for all outcomes; this approach links the numerical effect estimates to the confidence we placed in these estimates in formulating conclusions. <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> used the Jadad scale (<a href="./references#CD007953-bbs2-0077" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. ">Jadad 1996</a>) to assess study quality. There are problems reported in using summary scores from scales to assess methodological quality (<a href="./references#CD007953-bbs2-0078" title="JuniP , WitschiA , BlochR , EggerM . The hazards of scoring the quality of clinical trials for meta‐analysis. JAMA1999;282(11):1054‐60. ">Juni 1999</a>). Moreover, <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> reported that "Out of four studies, three scored 2 on Jadad’s 5 point scale while one study scored 3 points suggesting that these studies were not of very good quality." However, this assessment of study limitations were not reflected in the review's conclusions that, "Twice‐weekly intermittent short course therapy is less likely to cure TB in children as compared to daily therapy." Our interpretation of the evidence from the same four trials included in our review and in <a href="./references#CD007953-bbs2-0090" title="MenonPR , LodhaR , SivanandanS , KabraSK . Intermittent or daily short course chemotherapy for tuberculosis in children: meta‐analysis of randomized controlled trials. Indian Pediatrics2010;47(1):67‐73. ">Menon 2010</a> does not support this conclusion. </p> </li> </ol> </p> <p>The two other studies included in the WHO rapid advice (<a href="./references#CD007953-bbs2-0116" title="World Health Organization. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010a</a>; <a href="./references#CD007953-bbs2-0117" title="World Health Organization. Annex 1 ‐ Evidence summary tables. Rapid Advice. Treatment of tuberculosis in children. Geneva: World Health Organization, 2010. ">WHO 2010b</a>) evaluating intermittent versus daily treatments were a retrospective review of 130 children aged six months to 17 years (<a href="./references#CD007953-bbs2-0020" title="GöçmenA , ÖzçelicU , KiperM , ToppareM , KayaS , CengizlierR , et al. Short course intermittent chemotherapy in childhood tuberculosis. Infection1993;21(5):324‐7. ">Göçmen 1993</a>), and a prospective cohort of 185 children aged five months to 17 years (<a href="./references#CD007953-bbs2-0005" title="Al‐DossaryFS , OngLT , CorreaAG , StarkeJR . Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy. Pediatric Infectious Disease Journal2002;21(2):91‐7. ">Al‐Dossary 2002</a>) that evaluated partially intermittent treatments only without a daily treatment comparison arm. </p> <p>We are not aware of any other systematic review evaluating the efficacy of intermittent versus daily treatment in children alone. <a href="./references#CD007953-bbs2-0056" title="ChangKC , LeungCC , GrossetJ , YewWW . Treatment of tuberculosis and optimal dosing schedules. Thorax2011;66(11):997‐1007. ">Chang 2011</a> systematically reviewed the evidence on TB dosing schedules and efficacy and included nine systematic reviews, eight controlled studies, nine pharmacokinetic‐pharmacodynamic studies, and six animal studies. The clinical studies were mainly done on adults with TB and the review endorsed the use of daily dosing schedules, "especially during the initial phase in the presence of cavitation, INH resistance and advanced HIV co‐infection, to reduce the risk of treatment failure, recurrence and acquired drug resistance, including acquired rifamycin resistance" (<a href="./references#CD007953-bbs2-0056" title="ChangKC , LeungCC , GrossetJ , YewWW . Treatment of tuberculosis and optimal dosing schedules. Thorax2011;66(11):997‐1007. ">Chang 2011</a>). These caveats may well apply in childhood TB; but most cases of childhood pulmonary TB, particularly in younger children less than 10 years of age are not associated with cavitation (<a href="./references#CD007953-bbs2-0086" title="MaraisBJ , GieRP , SchaafHS , HesselingAC , ObiharaCC , StarkeJJ , et al. The natural history of childhood intra‐thoracic tuberculosis: a critical review of literature from the pre‐chemotherapy era. International Journal of Tuberculosis and Lung Disease2004;8(4):392‐402. ">Marais 2004</a>); and drug resistant TB, though increasingly a matter of concern, is not as widespread as in adults. </p> <p>The evidence from our review indicates that the there is uncertainty regarding the comparative efficacy of intermittent short‐course versus daily short‐course anti‐TB treatment regimens; but no convincing evidence that daily short‐course anti‐TB treatment is superior to intermittent short‐course anti‐TB treatment in children with TB. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007953-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of the selection process." data-id="CD007953-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of the selection process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included trials." data-id="CD007953-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included trial." data-id="CD007953-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot: 1. Intermittent versus daily regimens, Outcome 1.1 Cure (as defined by clinical and radiological improvement): Intention to treat." data-id="CD007953-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot: 1. Intermittent versus daily regimens, Outcome 1.1 Cure (as defined by clinical and radiological improvement): Intention to treat. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot: 1. Intermittent versus daily regimens, Outcome 1.5 Adherence to treatment." data-id="CD007953-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot: 1. Intermittent versus daily regimens, Outcome 1.5 Adherence to treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intermittent versus daily regimens, Outcome 1 Cure (as defined by clinical and radiological improvement): Intention to treat." data-id="CD007953-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intermittent versus daily regimens, Outcome 1 Cure (as defined by clinical and radiological improvement): Intention to treat. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#CD007953-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intermittent versus daily regimens, Outcome 2 Cure (as defined by clinical and radiological improvement): Per‐protocol (Sensitivity analysis)." data-id="CD007953-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intermittent versus daily regimens, Outcome 2 Cure (as defined by clinical and radiological improvement): Per‐protocol (Sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#CD007953-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intermittent versus daily regimens, Outcome 3 Death from any cause." data-id="CD007953-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intermittent versus daily regimens, Outcome 3 Death from any cause.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#CD007953-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intermittent versus daily regimens, Outcome 4 Relapse." data-id="CD007953-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intermittent versus daily regimens, Outcome 4 Relapse.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#CD007953-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intermittent versus daily regimens, Outcome 5 Adherence to treatment." data-id="CD007953-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intermittent versus daily regimens, Outcome 5 Adherence to treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#CD007953-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007953-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/urn:x-wiley:14651858:media:CD007953:CD007953-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_t/tCD007953-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intermittent versus daily regimens, Outcome 6 Treatment‐limiting adverse events." data-id="CD007953-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Intermittent versus daily regimens, Outcome 6 Treatment‐limiting adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#CD007953-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/media/CDSR/CD007953/image_n/nCD007953-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007953-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intermittent short‐course anti‐TB regimens compared to daily anti‐TB regimens for treating TB in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intermittent short‐course anti‐TB regimens compared to daily anti‐TB regimens for treating TB in children with TB</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Children with TB<sup>1</sup> <br/> <b>Intervention:</b> Intermittent short‐course twice‐weekly anti‐TB regimens (six to nine months)<br/> <b>Comparison:</b> Daily anti‐TB regimens (six to 12 months) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Daily anti‐TB regimens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intermittent short‐course anti‐TB regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cure</b> </p> <p>Follow‐up: 12 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>836 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>844 per 1000</b> <br/> (786 to 920) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/> (0.94 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death from any cause</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (2 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.52</b> <br/> (0.26 to 8.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213<br/> (2 trials)<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>,3,7,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> </p> <p>Follow‐up: 12 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.68</b> <br/> (0.15 to 89.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214<br/> (1 trial)<sup>10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>11,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence to treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>840 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>874 per 1000</b> <br/> (815 to 932) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> (0.97, 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>3,4,14,15</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐limiting adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (1 to 39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.4</b> <br/> (0.06 to 2.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,16</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies for pooled data and the control group risk for data from single studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The data in this table are from <a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a>; <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a>; <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a>; and <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>.<br/> <sup>2</sup> Downgraded by 1 for serious risk of bias: None of the trials were free of risk of bias. The trial that contributed the most weight (43%) to the pooled effect estimates (<a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>) was at high risk of selection bias.<br/> <sup>3</sup> No serious inconsistency<i>:</i> Statistical heterogeneity was low.<br/> <sup>4</sup> Downgraded by 1 for serious indirectness: Two of the trials (<a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a>; <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a>) used a longer duration of treatment in the daily treatment arms than in the intermittent arms, and the intermittent arms in <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> and <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> used non‐standard regimens. None used drug combinations and schedules currently recommended for childhood TB.<br/> <sup>5</sup> Downgraded by 1 for serious imprecision: The 95% CI of the effect estimate indicated only non‐appreciable benefit with both interventions, but the sample size was smaller than the optimal information size for equivalence.<br/> <sup>6</sup> Data for deaths are from only two of the four trials as no deaths were reported in <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a> and <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>.<br/> <sup>7</sup> Downgraded by 1 for serious risk of bias: The trials were either unclear or at high risk of selection bias.<br/> <sup>8</sup> Downgraded by 1 for serious indirectness: Neither control group used drug combinations and schedules currently recommended for childhood TB.<br/> <sup>9</sup> Downgraded by 1 for serious imprecision: The number of deaths was very few, and the 95% CI for the risk difference are wide. </p> <p><sup>10</sup> Data for relapse are from only one trial (<a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>) as no participant was reported to have had a confirmed relapse in <a href="./references#CD007953-bbs2-0001" title="KansoyS , KurtaşN , AkşítS , AksoylarS , YaprakI , ÇağlayanS . Superiority of intermittent‐short course chemotherapy in childhood pulmonary tuberculosis. Turkish Journal of Medical Sciences1996;26(1):41‐3. ">Kansoy (Turkey) 1996</a>; <a href="./references#CD007953-bbs2-0002" title="KumarL , DhandR , SinghiPD , RaoKL , KatariyaS . A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal1990;9(11):802‐6. ">Kumar (India) 1990</a>; and <a href="./references#CD007953-bbs2-0003" title="RamachandranP , KripasankarA S , DuraipandianM . Shortcourse chemotherapy for pulmonary tuberculosis in children. Indian Journal of Tuberculosis1998;45:83–7. ">Ramachandran (India) 1998</a> over one to five years of follow‐up.<br/> <sup>11</sup> No serious study limitations: Only one relapse was reported with intermittent treatment in <a href="./references#CD007953-bbs2-0004" title="TeWater NaudeJM , DonaldPR , HusseyGD , KipelMA , LouwA , PerkinsDR , et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatric Infectious Disease Journal2000;19(5):405‐10. ">Te Water Naude (South Africa) 2000</a>. This trial was at high risk of selection bias, but this is unlikely to have introduced bias in relapse estimates.<br/> <sup>12</sup> Downgraded by 1 for serious indirectness: The data for relapse comes from only one trial conducted in South Africa nearly 20 years ago and may not generalize to other settings today. </p> <p><sup>13</sup>Downgraded by 2 for serious imprecision: Only one child relapsed and the upper and lower limits of the 95% CI indicate appreciable benefits for both interventions with so significant differences.<br/> <sup>14</sup> Downgraded by 1 for serious risk of bias<i>:</i> The trials were open label in design and assessments of adherence were not done blind to treatment allocation The four trials used different methods to assess adherence and different definitions to define those adherent.<br/> <sup>15</sup> Downgraded by 1 for serious imprecision: The 95% CI of the pooled effect estimates indicated that the interventions did not appreciably increase adherence.<br/> <sup>16</sup> Downgraded by 1 for serious imprecision<i>:</i> Adverse events were infrequent and the 95% CI of the absolute risk difference indicated a non‐appreciable difference in the risk of adverse events requiring treatment interruptions with intermittent and with daily treatments. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intermittent short‐course anti‐TB regimens compared to daily anti‐TB regimens for treating TB in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/full#CD007953-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007953-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intermittent versus daily regimens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cure (as defined by clinical and radiological improvement): Intention to treat <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Intermittent (daily 2 weeks, twice‐weekly 8.5 months) versus daily treatment (12 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.95, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Intermittent (twice‐weekly 6 months) versus daily treatment (daily 2 months, intermittent 4 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Intermittent (thrice‐weekly 2 months, twice‐weekly 4 months) versus daily treatment (9 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Intermittent (twice‐weekly 6 months) versus daily treatment (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cure (as defined by clinical and radiological improvement): Per‐protocol (Sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Intermittent (daily 2 weeks, twice‐weekly 8.5 months) versus daily treatment (12 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.89, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Intermittent (twice‐weekly 6 months) versus daily treatment (daily 2 months, intermittent 4 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.93, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Intermittent (thrice‐weekly 2 months, twice‐weekly 4 months) versus daily treatment (9 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.60, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Intermittent (twice‐weekly 6 months) versus daily treatment (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Death from any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.26, 8.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [0.15, 89.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adherence to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.97, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Treatment‐limiting adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.06, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intermittent versus daily regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007953.pub2/references#CD007953-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007953.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007953-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007953-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007953-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007953\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007953\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007953\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007953\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007953\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007953.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007953.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007953.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007953.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007953.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716307886"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007953.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716307890"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007953.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9c434ae81bf6',t:'MTc0MDcxNjMwOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 